The role of transforming growth factor beta1 and its targets in pulmonary arterial hypertension by Kouri, Fotini Margarita
The Role of Transforming Growth Factor-1 and its Targets 
in Pulmonary Arterial Hypertension 
 
Inaugural Dissertation 
submitted to the 
Faculty of Medicine 
in partial fulfillment of the requirements  
for the PhD-Degree 
of the Faculties of Veterinary Medicine and Medicine 
of the Justus Liebig University Giessen 
 
 
 
by 
Fotini Margarita Kouri 
of 
Corfu, Greece 
 
 
 
 
Giessen 2009 
 From the Department of Medicine 
Director / Chairman: Prof. Dr. Werner Seeger 
of Medicine of the Justus Liebig University Giessen 
 
First Supervisor and Committee Member: 
Second Supervisor and Committee Member: 
Committee Members:
Table of contents 
I 
Table of contents 
Table of contents ······························································································ I 
List of figures ································································································ IV 
List of tables ··································································································· V 
List of abbreviations ······················································································ VI 
Summary ······································································································· IX 
Zusammenfassung ·························································································· X 
1. Introduction ······························································································· 1 
1.1 The pulmonary vascular system ································································· 1 
1.2 Structure of pulmonary arteries ································································· 2 
1.3 Pulmonary arterial hypertension ································································ 5 
1.4 Histopathologic features of PAH ······························································· 6 
1.4.1 Cellular remodelling ··············································································· 6 
1.4.2 Extracellular remodelling ······································································· 8 
1.5 Pathomechanisms of IPAH ········································································ 9 
1.5.1 Vasodilators: nitric oxide and prostacyclins ··········································· 9 
1.5.2 Vasoconstrictors: endothelin-1, thromboxane and serotonin················· 10 
1.6 Genetics of PAH ······················································································ 11 
1.7 Bone morphogenetic protein receptor type II ··········································· 11 
1.8 Experimental models of PAH ·································································· 12 
1.8.1 Hypoxia-induced PH ············································································ 12 
1.8.2 Monocrotaline-induced PH ··································································· 13 
1.8.3 Transgenic mice ···················································································· 13 
1.9 The TGF-/BMP signalling pathway ······················································· 14 
1.9.1 TGF- ligands ······················································································ 15 
1.9.2 TGF- receptors ··················································································· 15 
1.10 TGF- in PAH ······················································································· 16 
Hypothesis and aims of the study ·································································· 18 
2. Materials ·································································································· 19 
2.1 Reagents ·································································································· 19 
2.2 Equipment ······························································································· 20 
2.3 Methods ··································································································· 23 
Table of contents 
II 
2.3.1 Patient Population ················································································· 21 
2.3.2 RNA isolation and Polymerase Chain Reaction ···································· 22 
2.3.3 Protein Isolation and Western Blotting ················································· 23 
2.3.4 Immunofluorescence············································································· 24 
2.3.5 Cytokine stimulation ············································································· 24 
2.3.6 Immunohistochemistry ········································································· 26 
2.3.7 Isolation and Culture of human primary PASMC ································· 26 
2.3.8 Small interference RNA (siRNA) ························································· 27 
2.3.9 Proliferation assay ················································································ 27 
2.3.10 Migration/chemotaxis assay ································································ 27 
2.3.11 Adhesion assay ··················································································· 28 
2.3.12 GAG isolation and purification ··························································· 28 
2.3.13 Cellulose acetate electrophoresis ························································ 29 
2.3.14 GAG characterisation ········································································· 29 
2.3.15 HA measurements ··············································································· 30 
2.3.16 Measurement of total GAG synthesis ················································· 30 
2.3.17 Statistical Analysis·············································································· 31 
3. Results ······································································································ 32 
3.1 PAI-1 expression in IPAH and donor lungs ············································· 32 
3.2 PAI-1 localisation in the human lung ······················································· 33 
3.3 TGF-1-dependent PAI-1 upregulation in PASMC ································· 34 
3.4 PAI-1 localisation in PASMC ·································································· 35 
3.5 PAI-1 regulates PASMC proliferation ····················································· 35 
3.6 PAI-1 Regulates PASMC Migration and Adhesion ································· 37 
3.7 Differential expression of GAGs in IPAH ··············································· 38 
3.8 Changes in exrpression of has1, cd44 and hyal1 in IPAH ······················· 40 
3.9 IPAH is associated with increased distribution of HA in the lung ··········· 41 
3.10 TGF-1 Stimulates GAG Secretion and Deposition by PASMC ··········· 42 
3.11 TGF-1 stimulates HA secretion by PASMC ········································ 44 
3.12 TGF-1 Regulates has1 Expression in PASMC ···································· 44 
4. Discussion ································································································· 46 
4.1 Differential expression of PAI-1 in IPAH ················································ 46 
4.2 Plasminogen activator inhibitor 1 ···························································· 46 
4.3 PAI-1 and the vessel wall ········································································ 47 
Table of contents 
III 
4.4 Plasminogen inhibitor type 1 in IPAH ····················································· 48 
4.5 The role of HA in IPAH ·········································································· 49 
4.6 Hyaluronic acid: Jekyll or Hyde ······························································ 51 
4.7 Conclusion and future directions ····························································· 51 
5. Declaration ······························································································· 53 
6. Curriculum Vitae ····················································································· 54 
7. Acknowledgements ·················································································· 58 
8. References ································································································ 59 
 
List of figures 
 IV
List of figures 
Figure 1: The pulmonary circulation. ······························································ 1 
Figure 2: Cross section of a pulmonary artery. ················································ 2 
Figure 3: Alterations in the vessel wall in PAH. ·············································· 7 
Figure 4: Pulmonary vascular remodelling. ····················································· 8 
Figure 5: The bmpr2 gene.············································································· 12 
Figure 6: The TGF-/BMP signalling cascade. ············································· 14 
Figure 7: The mRNA and protein expression of PAI-1 in lung  
homogenates of IPAH patient and donors. ···················································· 32 
Figure 8: Localisation of PAI-1 in IPAH patient and donor lung tissue. ········ 33 
Figure 9: Reduced levels of PAI-1 in IPAH-derived PASMC. ······················ 33 
Figure 10: TGF-1-dependent PAI-1 regulation in PASMC. ························ 34 
Figure 11: Localisation of PAI-1 in cultured PASMC. ·································· 35 
Figure 12: PAI-1 inhibits PASMC proliferation. ··········································· 36 
Figure 13: PAI-1 induces PASMC migration. ··············································· 37 
Figure 14: PAI-1 reduces PASMC adhesion on vitronectin. ·························· 38 
Figure 15: GAG expression in IPAH. ···························································· 40 
Figure 16: Differential expression of has1, hyal1, cd44 in lungs of  
IPAH patients. ······························································································· 41 
Figure 17: Localisation of HA in IPAH patient and donor lung tissue. ·········· 42 
Figure 18: Effect of TGF-1 on GAG secretion and deposition 
in PASMC. ···································································································· 43 
Figure 19: Effect of TGF-1 on HA secretion by PASMC. ··························· 44 
Figure 20: Induction of has1 gene expression in TGF-1-stimulated  
PASMC. ········································································································ 45 
 
 
List of tables 
 V
List of tables 
Table 1: Primer sequences  ············································································ 25 
Table 2: GAG identification ·········································································· 39 
 
 
List of abbreviations 
 VI
List of abbreviations 
ALI  = Acute lung injury 
ALK1/5 = Activin receptor-like kinase 1/5 
SMA  = Alpha smooth muscle actin 
BMP  = Bone morphogenetic protein 
BMPRII = Bone morphogenetic protein receptor type II 
BMPRIA/B = Bone morphogenetic protein receptor type IA/B 
Col  = Collagen 
cAMP   = Cyclic adenosine monophosphate 
cGMP   = Cyclic guanosine monophosphate 
CT               = Connective tissue 
DAB               = Diaminobenzidine 
dNTP  = Deoxy nucleotide triphosphate 
EC  = Endothelial cells 
ECM  = Extracellular matrix 
EDTA  = Eythelene diamino tetra acetic acid 
EC        = Endothelial cells 
eNOS    = Endothelial nitric oxide synthase 
EL  = Elastic lamina 
ELISA  = Enzyme linked immunosorbent assay 
ERK  = Extracellular signal-regulated kinase 
ET-1  = Endothelin 1 
FCS      = Foetal calf serum 
FIB  = Fibroblast 
FITC  = Fluorescein isothiocyanate 
FPAH  = Familial pulmonary arterial hypertension 
GAG     = Glucosaminoglycan 
GAPDH     = Glyceraldehyde 3-phosphate dehydrogenase 
GDF     = Growth differentiation factor 
5HHT        = Serotonin transporter 
HA        = Hyaluronic acid 
HABP        = Hyaluronan binding protein 
HPRT-1        = Hypoxanthine phosphoribosyl transferase 1 
List of abbreviations 
VII 
HRP  = Horse-radish peroxidase 
HSC70            = Heat shock protein 70 
IPAH  = Idiopathic pulmonary arterial hypertension 
KU  = Kunitz unit 
JNK  = C-Jun-N-terminal kinase 
LAP  = Latency associated protein 
LLC  = Large latent complex  
LTBP  = Latent TGF--binding protein  
MAPK = Mitogen-activated protein kinase 
MMP  = Matrix metalloproteinase 
mRNA = messenger RNA 
NO  = Nitric oxide 
OD  = Optical density 
PAH  = Pulmonary arterial hypertension 
PAI-1  = Plasminogen activator inhibitor 1 
PASMC = Pulmonary arterial smooth muscle cells 
PBS  = Phosphate buffered saline 
PCR  = Polymerase chain reaction 
PDGF  = Platelet derived growth factor 
PECAM-1 = Platelet endothelial cell adhesion molecule 1 
PH  = Pulmonary hypertension 
rPAI-1  = Recombinant plasminogen activator inhibitor 1 
RT  = Reverse transcriptase 
SDS  = Sodium dodecyl sulfate 
SDS-PAGE = Sodium dodecyl sulfate - polyacrylamide gel electrophoresis  
siRNA  = Small interfering RNA 
SLC  = Small latent complex 
SMC  = Smooth muscle cells 
SPAH  = Secondary pulmonary arterial hypertension 
TBS  = Tris buffered saline 
TBST  = Tris buffered saline tween 
TGF-  = Transforming growth factor- 
TGF- RII = Transforming growth factor- receptor type II 
TF         = Tissue factor 
List of abbreviations 
VIII 
tPA         = Tissue-type plasminogen activator 
Tris  = Tris(hydroxymethyl)aminomethane 
VEGF   = Vascular endothelial growth factor 
VEGF-R2   = Vascular endothelial growth factor receptor type 2 
VSMC   = Vascular smooth muscle cells 
uPA         = urokinase-type plasminogen activator 
uPAR         = urokinase-type plasminogen activator receptor
Summary 
 IX
Summary 
Idiopathic pulmonary arterial hypertension (IPAH) is a rare but fatal disease affecting 
the pulmonary arteries. The hallmark of IPAH is excessive vascular remodelling of the 
pulmonary arteries, a well coordinated process, where all cell types of the vessel wall 
participate. The discovery that mutations in the gene coding for the bone morphogenetic 
protein receptor type 2 (bmpr2) as well as for the activin receptor-like kinase 1 (alk1), 
both members of the transforming growth factor (TGF)- receptor superfamily, in 
familial (IPAH) and secondary (SPAH) pulmonary arterial hypertension, respectively, 
suggest that the TGF- signalling cascade is important for the maintenance of the 
pulmonary vascular homeostasis and disease development. Hence, the aim of this study 
was to elucidate the role of the TGF- signalling cascade in the development of IPAH 
focusing on two aspects. First, the proliferation, migration and adhesion of pulmonary 
arterial smooth muscle cells and second the extracellular matrix deposition. 
Differential expression analysis between donor and IPAH lung homogenates revealed 
that the plasminogen activator inhibitor type I (PAI-1), a TGF-1 target gene, is 
significantly downregulated in IPAH lung homogenates, both on the mRNA and protein 
levels. Further in vitro experiments revealed that PAI-1 regulates PASMC proliferation, 
migration and adhesion and, therefore, could be a potential regulator of vascular 
remodelling in IPAH. Furthermore, the deposition of hyaluronic acid (HA), which is an 
important component of the lung extracellular matrix, is greatly increased in IPAH lungs 
compared to donors, due to increased levels of hyaluronan synthase 1 (HAS1), which is 
responsible for HA synthesis, and decreased levels of hyaluronoglucosamininidase 1 
(HYAL1), which degrades HA. In vitro experiments in PASMC revealed that TGF-1 
controls the levels of HA by regulating HAS1 expression levels.  
In summary, TGF-1 is a potent regulator of vascular remodelling contributing to IPAH, 
by controlling the levels of PAI-1 and HA.
Zusammenfassung 
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Zusammenfassung 
Die idiopatische pulmonale arterielle Hypertonie (IPAH) ist eine seltene, aber tödlich 
verlaufende Erkrakung der kleinen pulmonalen Arterien. Kennzeichnend fr diese 
Erkrankung ist der verstärkte vaskuläre Umbau der Pulmonalarterien, an dem alle 
Zelltypen der Gefäwand beteiligt sind. Die Entdeckung von Mutationen in den Genen 
des “bone morphogenetic protein” Rezeptors Typ 2 (bmpr2)” sowie des “activin 
receptor-like kinase 1 (alk1)” Rezeptors, beides Mitglieder der TGF-1 Superfamilie, 
deutet darauf hin das die Signalkaskade von TGF-1 eine wichtige Rolle in der 
Aufrechterhaltung der Gefä-Homöostase und in der Entstehung der Erkrankung spielt. 
Das Ziel dieser Studie war es die exakte Rolle des TGF-1 Signalweges in der 
Entwicklung von IPAH mit dem besonderen Fokus auf der Adhäsion, Proliferation und 
Migration von pulmonalen arteriellen glatten Muskelzellen (PASMC) sowie dem 
Prozess der Ablagerung von extrazellulärer Matrix zu untersuchen. 
Differentielle Expressionsanalyse von Homogenaten von Spender- und IPAH-Lungen 
zeigte, dass der Plasminogen Aktivator Inhibitor Type I (PAI-1), ein TGF-1 Zielgen, 
in IPAH-Lungen auf der m-RNA-Ebene sowie der Proteinebene signifikant 
herunterreguliert ist. 
Weitere in vitro Experimente demonstrierten das PAI-1 die Adhäsion, Proliferation und 
Migration von PASMC reguliert und daher eine potentieller Regulator der 
Gefäveränderungen in IPAH sein könnte. 
Weiterhin war die Ablagerung von Hyaluronsäure (HA), einem wichtigen Bestandteil 
der extrazellulären Matrix der Lunge, in Lungen von IPAH Patienten im Vergleich zu 
Spenderlungen beträchtlich Erhöht, und zwar durch erhöhte Level an Hyaluronsäure 
Synthetase 1 (HAS1), welche HA synthetisiert, und die gleichzeitige, reduzierte 
Expression der Hyaluronoglucosaminidase 1 (HYAL1), die für den Abbau von HA 
verantworltlich ist. In in vitro Experimenten mit PASMC konnte gezeigt werden, das 
TGF-1 die Synthese und den Abbau von HA durch die Regulation von HAS1 und 
HYAL1 kontrolliert. 
Zusammengefasst zeit die vorliegende Studie, dass TGF-1ber die Kontrolle der 
Level von PAI-1 und HA einen wichtigen Regulator, der Gefäwandumwandlung im 
Rahmen der Entstehung einer IPAH darstellt.  
Introduction 
 1
1. Introduction 
1.1 The pulmonary vascular system 
The lung is the vital organ where blood oxygenation and release of carbon dioxide 
occurs. The blood supply in the lung divides into the pulmonary and bronchial 
circulation. The pulmonary circulation carries deoxygenated blood from the right 
ventricle and is responsible for gas exchange at the alveolo-capillary level. The 
bronchial circulation, in contrast, is responsible for the maintenance of the gas 
exchanging units and the conducting airways of the lung, by providing oxygenated 
blood pumped from the left ventricle.  
The pulmonary circulation is a high flow, low pressure system, with properties distinct 
from that of the systemic circulation. The pulmonary vasculature of adults consists of 
large arteries, which branch out to smaller diameter vessels, with capillaries being the 
smallest vessel unit (Stevens, Phan et al. 2008).  
 
 
 
Figure 1: The pulmonary circulation. This is a schematic representation of the pulmonary 
circulation, demonstrating how the pulmonary arteries and veins run in parallel with the bronchiole, and 
then branch out to the capillary beds (virtualmedicalcentre 2006). 
 
The pulmonary circulation starts with the pulmonary artery dividing and entering each 
lung at the hilum, adjacent to the bronchus. The axial arteries travel adjacent to the 
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bronchus, although there is greater number of arteries in comparison to bronchi. The 
distinct feature of the pulmonary circulation, compared to the systemic circulation, is 
the branching into precapillary arteries, which form a diffuse network of capillaries, 
where gas exchange takes place, and which later drain into postcapillary veins. The 
pulmonary vein will finally carry the oxygenated blood to the left atrium and ventricle 
of the heart and then to the rest of the body via the aorta. In the pulmonary circulation, 
it is the pulmonary artery that carries deoxygenated blood and the vein the oxygenated 
blood, in opposition to the systemic circulation. A further vital and distinct feature of 
the pulmonary vasculature is the ability to detect the less ventilated and oxygenated 
areas in the lung, which orientates blood flow to the better ventilated areas. 
1.2 Structure of pulmonary arteries 
The size and cell types of the pulmonary arteries depend on their location in the 
vascular tree. As the blood flows from the right ventricle and back to the left atrium it 
runs through different sizes of pulmonary arteries, such as large elastic pulmonary 
arteries, smaller muscular pulmonary arteries, precapillary vessels and finally 
capillaries. Each of these vessel types has a different structure, and serves a different 
goal.  The large pulmonary arteries are composed of several layers of elastic lamina 
separated by endothelial and smooth muscle cells, fibroblasts and extracellular matrix. 
Elastic laminae are present in vessels of 1000 m in diameter. Muscular arteries 
appear next in the vessel tree, which are composed of three different cell types, each 
with its own distinct function and characteristics. The endothelial cells line the inner 
surface of the vessel and are in contact with the blood.  
 
Figure 2: Cross section of a pulmonary artery. This is a schematic representation of a 
pulmonary muscularised artery, consisting of three cell layers. EC: endothelial cells, PASMC: 
pulmonary arterial smooth muscle cells, FIB: adventitial fibroblasts, EL: elastic lamina, CT: connective 
tissue. 
 
PASMC 
FIB CT 
EC 
EL 
Introduction 
3 
The smooth muscle cells, which are localised in the medial layer of the vessel and the 
adventitial fibroblasts, which are found in the outer layer of the vessel. 
The precapillary vessels are composed of an endothelial cell layer surrounded by a 
basement membrane and pericytes, which serve multiple functions, such as the 
maintenance of the vessel wall. For example, upon injury of the vessel wall, pericytes 
transdifferentiate, aiding the repair process. In the precapillary vessels, there is still a 
discontinuous smooth muscle cell layer, which is absent in the capillary vessels. The 
capillary vessel, the smallest unit in the pulmonary vascular tree, is composed of a thin 
endothelial cell layer (0.2-0.5 m) surrounded by a basolateral membrane. It is at the 
capillary level that the blood oxygenation takes place. The capillaries are adjacent to 
the alveoli, from which they are separated by a thin basement layer. The maintenance 
of the blood-airway barrier is essential, and a disturbance  to this barrier leads to 
serious pathological conditions, such as acute lung injury (ALI). 
Elucidating the physiology and function of the cellular types of the vessel wall enables 
a better understanding of the maintenance of pulmonary vascular homeostasis.  
The vascular wall is a dynamic environment. Moving from the inner side of the vessel 
to the outside, the first cell type encountered are the endothelial cells, which are 
essential for angiogenic processes, regulation of the blood pressure and leukocyte 
trafficking (Augustin, Kozian et al. 1994). It is of particular interest that macrovascular 
endothelial cells differ from the microvascular endothelial cells. The former derive 
from the mesenchyme, during vasculogenesis, whereas the microvascular endothelial 
cells derive from hemangioblasts, which are known endothelial and haematopoietic 
precursor cells (Risau 1995). Macrovascular endothelial cells are very versatile, and 
are known to regulate blood pressure, by controlling the levels of vasoconstrictors and 
vasodilators in the circulation. The microvascular endothelial cells, in contrast, 
participate only in the blood-alveoli interaction, and the exchange of nutrients and 
oxygen (Eichmann, Corbel et al. 1997).  
Genes that are known to regulate endothelial cell function, and in particular 
vasculogenesis and angiogenesis, are for example, the vascular endothelial growth 
factor (VEGF) and the vascular endothelial growth factor receptor 2 (VEGF-R2) 
(Ferrara and Henzel 1989; Leung, Cachianes et al. 1989; Carmeliet, Ferreira et al. 
1996). In addition, the angiopoietin1,2/Tie-2 system is known to regulate vessel 
maturation (Fong, Rossant et al. 1995; Hanahan and Folkman 1996). It is note worthy 
that endothelial cells belong to the category of slow replicating cells, and therefore are 
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generally found in a quiescent state. Below the endothelial cell layer lies the basement 
membrane, which plays an important role in separating the endothelium from the 
medial layer of the vessel, regulating the presence of different growth factors in close 
proximity to the endothelium, as well as maintaining the differentiation state of the 
endothelium.  
The medial layer is composed of smooth muscle cells, which have mesenchymal origin 
and constitute not only the vessel wall, but also the wall of trachea, bronchioles and 
intestines (Owens 1995). Their ability to contract, due to intracellular cytoskeletal 
structures, makes them a specialised cell type, responsible for the regulation of the 
vascular tone. It has been observed that smooth muscle cells in culture loose their 
ability to contract, but they are still capable of proliferating and synthesising 
components of the extracellular matrix (ECM) (Owens, Kumar et al. 2004). In humans, 
the medial layer of large pulmonary as well as systemic arteries contains different 
populations of smooth muscle cells, each with a different function, as is evident from 
studies on ion channels, proliferation and ECM deposition under differential stress 
conditions (Archer 1996; Durmowicz, Frid et al. 1996; Frid, Aldashev et al. 1997; 
Platoshyn, Remillard et al. 2004; Archer 2005). During the development of vascular 
disease, the smooth muscle cells which are less differentiated are those that undergo 
enhanced proliferation (Frid, Dempsey et al. 1997). The name “smooth” comes from 
the inability to distinguish any contractile structure under a light microscope. Several 
specific markers exist for smooth muscle cells, such as  smooth muscle actin 
(SMA), transgelin (or SM22), calponin, and smooth muscle-myosin heavy chain 
(SM-MHC). Pulmonary arterial smooth muscle cells (PASMC), apart from being 
contractile are also able to synthesise prostaglandins and a variety of cytokines and 
growth factors. Furthermore, PASMC regulate the formation of the arterial elastic 
lamina and components of the ECM, surrounding the cells in the vascular wall.  
The cells of the vessel interact in an autocrine-paracrine manner. PASMC are able to 
communicate with both endothelial cells and adventitial fibroblasts (Armulik, 
Abramsson et al. 2005). This communication is essential for vascular homeostasis 
(Stevens, Phan et al. 2008). The pulmonary endothelium, as being the major sensor 
and regulator of shear stress, generated by the blood flow, transmits any sensed 
changes to the underlying smooth muscle cell layer, leading to phenotypic and 
functional alterations. For example, under physiological conditions, endothelial cells 
synthesise and secrete nitric oxide (NO) leading to PASMC relaxation and subsequent 
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vessel dilation. In case of injury and endothelial cell damage, a series of events take 
place, which aim to repair the injury. In particular, the endothelium secretes tissue 
factor (TF) in order to initiate clot formation, and repair by activating platelets and 
induce fibrin deposition. When the injury has been repaired, fibrin plug resolution 
follows, which is effected by plasmin. Plasmin activity depends on the balance 
between plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1) 
(Fay, Garg et al. 2007). 
Endothelial cells can secrete factors, such as endothelin-1 (ET-1), a potent 
vasoconstrictor causing PASMC contraction. There is also a series of growth factors 
that are known to regulate PASMC function and response to injury, such as 
transforming growth factor-1 (TGF-1) and platelet derived growth factor (PDGF).  
The outer layer of the vessel wall, the adventitial layer, is composed of a 
heterogeneous population of fibroblasts. In a similar manner to PASMC, adventitial 
fibroblasts regulate ECM synthesis and synthesise growth factors that regulate 
PASMC function. Although less attention has been paid to the adventitial fibroblasts 
compared to the endothelial cells and PASMC, the adventitial layer is more important 
than was originally believed. The adventitial layer takes part in sensing of tissue injury 
and environmental stresses, and responds by fibroblast activation, increase in cell 
proliferation, ECM synthesis and secretion of factors that directly regulate the vascular 
tone (Hu, Zhang et al. 2004; Short, Nemenoff et al. 2004). Evidence suggests that 
during disease development, active fibroblasts or myofibroblasts migrate to the medial 
and intimal layers, contributing to vessel thickening (Stenmark, Davie et al. 2006). 
Furthermore, it is well accepted that during vascular remodelling, the cells of the 
vessel wall obtain a more myofibroblast-like phenotype, highlighting the potential 
importance of this cell type in tissue maintenance, as well as disease development 
(Jones, Jacobson et al. 1999).  
1.3 Pulmonary arterial hypertension 
Pulmonary arterial hypertension (PAH), which was first described over 100 years ago, 
is a rare but devastating disease, with an annual incidence of one to two individuals per 
one million of population. The main pathological feature of PAH is increased 
pulmonary vascular resistance and pressure (>25 mmHg at rest or >30 mmHg during 
exercise). It usually affects young women (female to male ratio 2:1) and if untreated, it 
leads to death due to right ventricular hypertrophy, dilation and failure (Humbert and 
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Trembath 2002; Humbert, Morrell et al. 2004; Eickelberg and Seeger 2005). Current 
available therapies are inadequate for complete disease treatment. PAH can be 
classified as idiopathic (IPAH), of unknown aetiology, familial (FPAH), which is 
inherited within families; and secondary (SPAH), due to an underlying disease, such as 
connective tissue diseases, cardiac defects, viral infections, portal hypertension, use of 
anorexigens, persistent pulmonary hypertension of the newborn and thromboembolic 
pulmonary hypertension (Humbert 2008). It is well appreciated that PAH is a complex 
disorder, requiring both environmental and genetic factors for its development (Morse, 
Deng et al. 2001; Elliott 2005). 
1.4 Histopathologic features of PAH 
1.4.1 Cellular remodelling 
The pathological hallmark of PAH is excessive vascular remodelling in the small 
pulmonary arteries, which is common among the different types of PAH. The process 
of vascular remodelling is well orchestrated and results in the occlusion of small 
vessels, due to changes in the intima, medial and adventitial layers, as well as 
excessive ECM deposition. In severe PAH, formation of plexiform lesions occur, 
which is a unique feature of the pulmonary vascular tree (Olschewski, Rose et al. 
2001). 
The process of vascular remodelling is complex, and its nature is dependent upon the 
size of pulmonary vessel. A large pulmonary vessel, for example, undergoes different 
changes than does a smaller muscular artery or a capillary.  
In more detail, the elastic and muscular arteries undergo medial hypertrophy and 
hyperplasia, which results in an increase in both the size and number of the PASMC, 
respectively. 
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Figure 3: Alterations in the vessel wall in PAH. The process of vascular remodelling 
occurring during PAH development is complex. Major features are the increased pulmonary vascular 
smooth muscle (PASMC) and endothelial cell (EC) proliferation, migration as well as ECM deposition. 
 
Furthermore, these cells undergo phenotypic changes that allow them to extend to the 
precapillary arteries, which are normally semi- or non-muscular. Medial thickening is 
usually followed by intimal thickening. Different patterns of intimal thickening have 
been observed. Concentric laminar fibrosis has characteristic “onion skin-like” layers 
of fibroblasts, myofibroblasts, and smooth muscle cells as well as acellular connective 
tissue. Other forms include the eccentric and concentric intimal thickening, where 
fibroblasts and connective tissue, which can, either localise to one part of the vessel or 
obliterate the entire lumen. Adventitial thickening due to uncontrolled fibroblast 
proliferation, is also observed, usually in pulmonary hypertension of the newborn 
(Olschewski, Rose et al. 2001).  
Focusing on the pre-capillary arteries, apart from the migrating smooth muscle cells 
there is evidence that their muscularisation occurs after differentiation of the 
surrounding pericytes (Yamagishi and Imaizumi 2005), deposition of circulating 
fibrocytes (Metz 2003) or even differentiation of endothelial cells to mesenchymal 
cells (EMT) (Arciniegas, Neves et al. 2005). Fibrocytes are a subpopulation of 
circulating leukocytes (CD45+, CD11b+) that are recruited to the injured area and take 
on a mesenchymal phenotype (expressing SMA and collagen) and function as 
myofibroblasts (Frid, Brunetti et al. 2006). Hypoxia is a known stress factor inducing 
Introduction 
8 
fibrocyte recruitment in the pulmonary vessels (Davie, Crossno et al. 2004). It is 
thought that fibrocytes also contribute in other fibroproliferative diseases of the lung, 
such as idiopathic pulmonary fibrosis (Phillips, Burdick et al. 2004).  
 
Figure 4: Pulmonary vascular remodelling. Photomicrographs illustrating lung sections 
derived from (A) a control subject and (B) a patient with IPAH stained for SMA, a marker of 
pulmonary arterial smooth muscle cells. 
 
Plexiform lesions, composed of proliferating endothelial cells and PASMC as well as 
myofibroblasts and ECM, are observed in severe PAH. The plexiform lesion usually 
arises at a vessel branch. The lumen of the lesion is replaced by vascular channels. The 
lesion can extend to the adventitial layer after destruction of the medial layer. It is now 
clear that some of the plexiform lesions arise from clonal expansion of endothelial 
cells that escape apoptosis.  
Thus, it is clear than disturbances in the regulation of cellular processes, such as 
proliferation, and migration are important for the development of pulmonary vascular 
remodelling. 
1.4.2 Extracellular remodelling 
The activation of PASMC and fibroblasts leading to the deposition of ECM, which 
increases pulmonary vessel wall striffness (Rabinovitch 2001; Hassoun 2005), is an 
important process taking place during vessel remodelling. In general, the ECM is 
composed of collagens, fibronectin, vitronectin, proteoglycans and 
glucosaminoglycans (Bosman and Stamenkovic 2003). In the lung, the ECM is subject 
to 10% daily turnover, thus, any alterations in the turnover time could induce great 
changes (McAnulty and Laurent 1987). Important ECM components as well are the 
glucosaminoglycans or GAGs, which are long, linear and negatively-charged 
polysaccharide molecules composed of disaccharide repeating units. The repeating unit 
is made of uronic acid (D-glucoronic acid, L-iduronic acid) and an amino sugar (D-
(A) (B) 
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galactosamine, D-glucosamine). They can be classified as sulfated, such as chondroitin 
sulfate, dermatan sulfate, keratan sulfate, heparin and heparan sulfate, or non-sulfated, 
such as hyaluronic acid (HA). With the only exception of HA, the rest of GAGs are 
covalently bound to proteins, giving rise to proteoglycans. The GAGs are known to 
participate and regulate several processes, such as vascular smooth muscle cell 
differentiation (Papakonstantinou, Karakiulakis et al. 2000; Papakonstantinou, Roth et 
al. 2001; Jiang, Liang et al. 2005), as well as cell proliferation, migration and plasticity 
(Papakonstantinou, Roth et al. 1998; Lee and Spicer 2000; Toole 2004). One member 
of the GAG family is the HA, which is a component of basement membranes and 
constitutes approximately 10% of all proteoglycans (Hance and Crystal 1975). The HA 
is synthesised by three hyaluonan synthases (HAS1-3), which have distinct properties, 
and which synthesise HA of different molecular mass (Itano, Sawai et al. 1999). After 
synthesis at the inner side of the cellular plasma membrane, HA is released into the 
extracellular space through pore-like structures. Furthermore, HA is degraded by four 
hyaluronoglucosaminidases (HYAL1-4), with HYAL1 having the highest activity 
(Csoka, Frost et al. 1997) 
Hence it is evident that an uncontrolled regulation of ECM synthesis is another key 
mechanism in the process of pulmonary vascular remodelling. 
1.5 Pathomechanisms of IPAH 
The pathogenesis of PAH remains unknown, however, many advances have occurred 
the past years regarding its better understanding and treatment. Pulmonary arterial 
hypertension, as a multifactorial disease, requires more than one genetic and 
environmental factor to lead to the observed pulmonary vascular wall changes, such as 
vasoconstriction and increased cell proliferation. It is considered that an initial 
endothelial cell dysfunction triggers an imbalance between vasoconstrictors and 
vasodilators, which further leads to an imbalance between growth inhibitors and 
mitogenic growth factors, causing unrestricted proliferation and ECM deposition by 
the underlying PASMC and adventitial fibroblasts (Farber and Loscalzo 2004).  
1.5.1 Vasodilators: nitric oxide and prostacyclins 
Vasodilators, such as NO and prostacyclins, lead to vessel dilation. Nitric oxide is a 
potent vasodilator. It is synthesised by endothelial cells of the vessel wall, by 
endothelial NO synthase (eNOS). Nitric oxide exerts its vasodilating effects on the 
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underlying vascular smooth muscle cells by increasing the levels of cyclic guanosine 
monophosphate (cGMP). Apart from its vasodilating effects, NO acts as an 
anticoagulant agent as well, it inhibits the adhesion of platelets on the vessel wall and 
thrombi formation. Furthermore, NO has been shown to regulate the proliferation of 
PASMC. Overexpression of NO in transgenic mice inhibits hypoxia-induced 
pulmonary hypertension (PH) (Chatterjee and Catravas 2008). In addition, 
prostacyclins are metabolites of arachidonic acid and are synthesised by pulmonary 
endothelial cells. Prostacyclin acts on adenylate cyclase that induces the synthesis of 
cyclic adenosine monophosphate (cAMP) and thus PASMC relaxation. Prostacyclin, 
like NO, has anticoagulant properties and inhibits smooth muscle cell proliferation. 
Administration of prostacyclin has also been used as a therapeutic option in patients 
with PAH (Aguilar and Farber 2000; Olschewski, Ghofrani et al. 2000; Wensel, Opitz 
et al. 2000).  
1.5.2 Vasoconstrictors: endothelin-1, thromboxane and serotonin  
Endothelin-1 (ET-1) is a potent vasoconstrictor. Endothelin-1 is highly expressed in 
the lung, and is synthesised by endothelial, smooth muscle and airway epithelial cells. 
It induces effects by binding to two types of receptors (ETA, ETB) on PASMC 
(Hassoun, Thappa et al. 1992). Thromboxane A2 is another arachidonic acid 
metabolite, synthesised by pulmonary endothelial cells and platelets, and apart from 
vasoconstriction, it induces platelet aggregation as well as PASMC proliferation 
(Fischer, Honemann et al. 2000). In addition, serotonin (5-HT), another 
vasoconstrictor, (Marcos, Fadel et al. 2004) exhibits elevated levels in the serum of 
patients with PAH, which remain high even after heart-lung transplant, suggesting that 
the increased levels of serotonin are a primary rather than a secondary effect. 
Interestingly, in the 1960s, it was documented that cases of PAH, which developed in 
France after aminorex use, which is an anorexigen, was due to increased serotonin 
levels. Furthermore, mutations in the serotonin transporter (5HHT) and the serotonin 
receptor were identified in patients with idiopathic and secondary PAH (Launay, 
Herve et al. 2002). Furthermore, 5HHT inhibition reversed monocrotaline-induced PH 
in rats (Guignabert, Raffestin et al. 2005) 
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1.6 Genetics of PAH 
The discovery of mutations in the bone morphogenetic protein receptor type 2 (bmpr2) 
gene in 60-70% of patients with FPAH, which account for about 6-7% of total PAH 
cases, and in a significant number (20%) of the sporadic cases, by linkage analysis, 
was pivotal for the further understanding of the disease pathogenesis (Deng, Morse et 
al. 2000; Lane, Machado et al. 2000; Thomson, Machado et al. 2000; Machado, 
Pauciulo et al. 2001). It is now known that more than 100 different mutations have 
been identified in patients, causing a reduction in the bmpr2 gene expression levels as 
well as alterations in BMPR2 function (Morrell 2006). Even in the absence of 
mutations in the bmpr2 gene, there are decreased expression levels in PAH patients. 
The bmpr2 gene is a member of the TGF- receptor superfamily and it regulates 
several different cellular processes, including cellular proliferation, differentiation and 
apoptosis (Zhang, Fantozzi et al. 2003; Tada, Majka et al. 2007). It was early 
recognised that the penetrance of these mutations was relatively low (about 20%), 
explaining why only a few of the carriers of the bmpr2 mutations will indeed develop 
PAH. The low penetrance of the mutations in the bmpr2 gene implies that other 
modifier genes are also involved in this process. In addition, there is genetic 
anticipation, meaning that each successive generation inheriting the mutations, will 
develop the disease at a younger age and in more severe form.   
Apart from the bmpr2 gene, mutations in the activin receptor-like kinase 1 (alk1) gene 
also member of the TGF- receptor superfamily, were also found in patients with 
SPAH (due to haemorrhagic telangiectasia) (Trembath, Thomson et al. 2001). This 
provides further evidence that the TGF-/BMP signalling cascade is involved in the 
process of pulmonary vascular homeostasis and disease development.  
1.7 Bone morphogenetic protein receptor type II 
The bone morphogenetic protein receptor type II is a member TGF- receptor 
superfamily. The bmpr2 gene is composed of 13 exons, where exon 12 is the largest. 
The BMPR2 protein contains an extracellular domain, which is responsible for the 
ligand binding, a small transmembrane part, and a cytoplasmatic kinase domain. 
Unlike the rest of the type II receptors of the TGF- superfamily, the BMPR2 protein 
has a long cytoplasmatic extension, which is responsible for intracellular signalling. 
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Figure 5: The bmpr2 gene. Schematic representation of the different domains of the BMPR2 
protein as well as the location of the described mutations (Bobik 2006). 
 
Mutations in the whole length of the bmpr2 gene have been identified in familial and 
idiopathic cases of PAH leading to perturbations to the BMP signalling cascade, which 
is initiated by bone morphogenetic proteins (BMP) such as, BMP2,4 and 7 (Bobik 
2006). Seventy percent of these mutations are frame-shift and nonsense mutations 
leading to nonsense mediated mRNA decay, and thus BMPR II haploinsufficiency. 
The remaining 30% of the mutations are missense mutations in conserved amino acids 
in the kinase domain or the extracellular ligand binding domain, affecting the receptor 
function (Machado, Aldred et al. 2006). 
1.8 Experimental models of PAH 
The existence of experimental animal models for PH is essential since they provide 
further insight into the disease pathogenesis and allow the development of novel 
strategies for the treatment. The best described and more frequently used are the 
hypoxia-induced PH in rodents (mouse and rat), as well as the monocrotaline-induced 
PH in the rat. These models have different origins of PH development and different 
manifestations of the disease. 
1.8.1 Hypoxia-induced PH 
In this model, the mice or rats are placed in hypoxic chambers, with the oxygen levels 
varying from 1-8% for up to four weeks. During this time, they develop pulmonary 
hypertension as evident from haemodynamic data. Vascular remodelling is observed as 
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thickning of the vessel wall, mainly due to uncontrolled proliferation of the PASMC, 
as well as muscularisation of non-muscular small arteries. The vascular remodelling is 
reversible and is mainly due to medial thickness in the mouse and moderate intimal 
thickness in the rat, and there is absence of plexiform lesion formation, which is 
usually found in severe cases of human PAH (Stenmark, Fagan et al. 2006).  
1.8.2 Monocrotaline-induced PH 
This model differs from the hypoxia-induced PH model in that healthy rats are 
subcutaneously or intraperitoneily injected with the alkaloid monocrotaline, which is 
derived from plants that belong to the Crotalaria genus (Lame, Jones et al. 2000). 
Monocrotaline, after activation in the liver to monocrotaline pyrrole, causes PH in four 
weeks, and the mechanism of action has been suggested to be an initial damage to the 
pulmonary endothelial cells, leading to remodelling in the pulmonary arterioles. It is 
clear that rats, four weeks post-monocrotaline administration, are unable to recover 
and die. It is thought that the remodelling observed after monocrotaline treatment is 
stronger than that observed after hypoxia treatment.  
1.8.3 Transgenic mice 
 Since the discovery of bmpr2 mutations in familial and sporadic cases of PAH, efforts 
were made focusing on the induction of PAH after deletion of the bmpr2 gene using 
transgenic mice. The bmpr2 -/- mice die very early, before gastrulation. The bmpr2 +/- 
mice are viable, and develop normally, without any pulmonary pathological features.  
Further research lead to the creation of a conditional, tissue specific bmpr2 transgenic 
mouse, the SM22-tet-BMPR2delx+4, which would conditionally express a dominant-
negative form of the bmpr2 gene in the vasculature. The dominant-negative form of 
the bmpr2 gene arises from a mutation found in the kinase domain of the receptor, 
which was originally identified in patients with the familial form of PAH. These 
conditional transgenic mice demonstrated features of PH, such as increased pulmonary 
arterial pressure, and arterial muscularisation. There was absence of plexiform lesions, 
as in the monocrotaline and hypoxia models described above (West, Fagan et al. 2004; 
West, Tada et al. 2005). 
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1.9 The TGF-/BMP signalling pathway 
Upon binding of the TGF-/BMP ligand to the type II or type I receptor (depending on 
the ligand), there is formation of a heterotetrameric complex, consisting of type I and 
type II receptor homodimers. The type II receptor activates the type I receptor by 
phosphorylation at specific serine residues at the glycine-serine rich domain, which is 
located upstream of the kinase domain. The activated type I receptor is essential for the 
initiation of the intracellular signaling cascade, since it will activate, by 
phosphorylation, the effector molecules called Smads. There are three different classes 
of Smad molecules. The receptor Smad or R-Smad, such as Smad 1, 2, 3, 5, 8, the 
common mediator Smad, such as Smad 4 and the inhibitory Smads, Smad 6 and 7. It is 
of particular interest the role of the TGF- in the development of PAH (Eickelberg and 
Morty 2007). Although two members of the TGF- receptor superfamily have been 
involved in the PAH pathogenesis the actual contribution of the TGF-/Smad 
signalling is not fully elucidated. 
Figure 6: The TGF-/BMP signalling cascade. Upon binding of the TGF-/BMP ligand to 
the type II and type I receptors there is initiation of the intracellular signalling cascade. The type I 
receptor activates the receptor mediated Smads (1,2,3,5,8) by phosphorylation, which together with 
Smad4 translocate to the nucleus to regulate gene expression. Apart from the Smad canonical signalling 
other pathways can be activated by TGF-/BMP, such as the p38 mitogen-activated protein kinase 
(MAPK), the extracellular signal-regulated kinase (ERK) and the C-Jun-N-terminal kinase (JNK). 
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1.9.1 TGF- ligands 
There are three TGF- isoforms, TGF-1, 2 and 3, which are abundantly expressed in 
the vascular cells, such as endothelial and smooth muscle cells, but also in 
macrophages and lymphocytes. The TGF- ligands are synthesised as inactive 
homodimers, which are covalently linked to the latency associated protein (LAP). 
Inactive TGF- can be cleaved to its active form, by several different molecules, such 
as plasmin, plasminogen activator receptor, thrombospondin and furin-like proprotein 
convertases. After its activation, TGF- remains non-covalently bound to the LAP, 
forming the small latent complex (SLC). In most cases, however, TGF- is found in 
the large latent complex (LLC). This is formed by the creation of a disulfide bond 
between the SLC and a member of the latent TGF--binding proteins (LTBP) within 
secretory vessels. In this form, TGF- cannot be recognised by the TGF- receptors on 
the plasma membrane, therefore TGF- must dissociate from the SLC or the LLC. 
There are different mechanisms regulating this process, such as proteolytic cleavage by 
MMPs, plasmin, thrombin, elastase, and recently integrins were reported to activate 
latent TGF- (Koli, Saharinen et al. 2001).      
1.9.2 TGF- receptors  
After TGF- activation, ligand binding to the TGF- receptors, on the plasma 
membrane, induces TGF- signals.  The TGF- ligands bind the type II receptor 
leading to the initiation of the intracellular pathway. Essential for triggering the 
intracellular signalling is the type I receptor, which is activated by the type II receptor. 
There are two types of type I receptors, ALK1 and ALK5, activated by the TGF- 
ligands. The ALK5 receptor is abundantly expressed, whereas ALK1 is reported to be 
present only on endothelial cells. In endothelial cells, TGF- can exert different effects 
depending on which type 1 receptor is activated. For example, ALK1-dependent 
signalling in endothelial cells induces cell proliferation and angiogenesis, while ALK5 
signalling in the same cell type promotes quiescence. Apart from the type I and type II 
receptors there is a class of type III accessory receptors tha facilitate the TGF- 
signalling, such as betaglycan and endoglin (Goumans, Liu et al. 2009). 
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1.10 TGF- in PAH 
The role of TGF- in vascular development and remodelling is controversial, due to 
the diversity of growth factors and receptors triggering opposite effects on different 
cell types. The TGF- superfamily is composed of more than thirty growth factors, 
among these, the prototype TGF-s, bone morphogenetic proteins, activins, growth 
differentiation factors (GDF) and inhibins have critical roles in development and 
homeostasis. The existence of two classes of transmembrane serine/threonine kinase 
receptors, each comprising several different types, contributes to this diversity of effect.  
The fact that mice lacking TGF-1 have vascular defects reveals the importance of this 
signalling pathway for normal vascular development and homeostasis. Deletion of the 
TGF-1 isoform causes 50% embryonic lethality due to defects in yolk sac 
vasculogenesis. Transgenic mice without the TGF- type I and type II receptors are 
also embryonic lethal due to defects in the yolk sac. Knock out of endoglin, an 
accessory TGF- receptor, in transgenic mice is also embryonic lethal due to 
cardiovascular and angiogenic effects. Mice deficient in Smad 1, 2 and 4 are lethal due 
to vascular problems, and Smad 3-deficient mice are viable, but eventually die due to 
colon cancer and immune system impairment. Mice lacking any of the inhibitory 
Smads develop cardiac defects, although they are viable. For example, Smad 6 
knockout mice develop heart abnormalities, and Smad 7 knockout mice die shortly 
after birth due to abnormal heart development (Goumans, Liu et al. 2009).  
Aberrations in TGF- signalling have been associated with vascular smooth muscle 
cell properties, which might be responsible for cardiovascular defects. Furthermore, in
vitro studies demonstrated that TGF- has different effects depending on the cell type 
of the vessel wall and the concentration. Low concentrations of TGF-1 can induce 
both endothelial and smooth muscle cell proliferation and migration. High levels of 
TGF- though can have the opposite effects on the same cell type. Less mechanistic 
insight is available concerning these effects on PASMC compared with endothelial 
cells. In PASMC, TGF-1 induces its effects via the ALK5/TGF- receptor type II 
induced pathway. It has been shown that the downstream signalling pathway does not 
only involve the Smad canonical signalling, but also the activation of other signalling 
cascades, including the p38 MAPK, p42/44 and JNK. Transforming growth factor-1 
is a potent regulator of vascular smooth muscle cell differentiation, by regulating the 
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expression levels of SMA, transgelin, calponin, smooth muscle-myosin heavy chain 
and other specific smooth muscle markers. It furthermore stimulates the proliferation 
of these cells, by inducing PDGF-AA as well as the synthesis of ECM components, 
such as fibronectin, type IV collagen and VEGF. The latter will further induce the 
endothelial cell migration and initiation of angiogenesis. The exact mechanism of how 
TGF- can also inhibit these processes at vascular smooth muscle cells it is not well 
understood. Transforming growth factor- expression is also known to be regulated by 
hypoxia. The inhibition of TGF- signalling by a dominant-negative mutant of TGF- 
RII blocked hypoxia-induced pulmonary vascular remodelling, indicating the 
importance of the TGF- signaling cascade for hypoxia-induced PH (Chen, Feng et al. 
2006).    
Over the last two years, a number of studies have been published illustrating that the 
inhibition of ALK5 in the monocrotaline model reversed PH. These are important 
studies and it is the first time shown that inhibition of the TGF- signalling pathway 
leads to reversal of PH (Long, Crosby et al. 2009; Thomas, Docx et al. 2009). These 
studies further support our hypothesis that that the TGF- signalling cascade is 
important for the maintenance of tissue homeostasis and development of PAH. 
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Hypothesis and aims of the study 
We hypothesised that aberrations in the TGF- signalling pathway can lead to PAH by 
regulating the function of PASMC, the cell type which is primarily involved in the 
process of vascular remodelling. 
Thus our aims were to  
 to identify members of the TGF- signalling cascade or TGF- gene targets that are 
differentially regulated in PAH as compared to healthy control subjects  
 to identify their role in the process of vascular remodelling focusing on the 
regulation of PASMC function  
Materials and Methods 
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2. Materials 
2.1 Reagents  
Acrylamide solution, Rotiphorese Gel 30 (Merck, Germany) 
Agarose (Invitrogen, UK) 
Ammonium persulfate (Promega, Germany) 
-mercaptoethanol (Sigma-Aldrich, Germany) 
Bromophenol blue (Sigma-Aldrich, Germany) 
Chondroitin ABC lyase (EC 4.2.2.4, Sigma-Aldrich, Germany) 
Chondroitin B lyase (Sigma-Aldrich, Germany) 
Chondroitin sulphate A (Sigma-Aldrich, Germany) 
Chondroitin sulphate B (Sigma-Aldrich, Germany) 
Chondroitin sulphate C (Sigma-Aldrich, Germany) 
Complement Mix (C-39267, PromoCell, UK)  
Dimethyl sulfoxide (Sigma-Aldrich, Germany) 
Dnase I (EC 3.1.21.1, Calbiochem, EMD Chemicals Inc., San Diego, CA, USA)  
Dulbecco’s phosphate-buffered saline (Laboratories, Austria) 
ELISA HABP plates (Corgenix, Westminster, UK) 
Ethanol absolute (Riedel-de Haen, Germany) 
Glycine (Roth, Germany) 
Heparan sulphate (Sigma-Aldrich, Germany) 
Heparin (Sigma-Aldrich, Germany) 
Heparin lyase I (EC 4.2.2.7, Seikagaku, Tokyo) 
Histostain-SP kit (Zymed, USA) 
Hyaluronate lyase (EC 4.2.2.1, Sigma-Aldrich, Germany) 
3H-glucosamine (Amersham Corp., Buckinhamshire, UK) 
3H-Thymidine (Amersham Corp., Buckinhamshire, UK) 
Keratan sulphate (Sigma-Aldrich, Germany) 
Keratan sulphate endo--D-galactosidase (EC 3.2.10.3, Sigma-Aldrich, Germany) 
Lipofectamine (Invitrogen, UK) 
Magnesium chloride (Promega, Germany) 
Methanol (Fluka, Germany) 
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Taq DNA polymerase (Promega, Germany) 
Precision Plus ProteinTM Standards (Bio-Rad, USA) 
Pronase (Calbiochem, EMD Chemicals Inc., San Diego, CA, USA) 
2-Propanol (Merck, Germany) 
Rnase inhibitor (Promega, Germany) 
RNA extraction kit (Roth, Germany) 
RNeasy mini kit (Qiagen, Germany) 
RNase H- reverse transcriptase (Promega, Germany)  
Smooth Muscle Cell Growth Medium 2 (PromoCell, UK) 
Sodium dodecyl sulfate (Promega, Germany) 
Tween 20 (Sigma-Aldrich, Germany) 
Tris (Roth, Germany) 
Triton X-100 (Promega, USA) 
Trypsin/EDTA (Gibco BRL, Germany) 
2.2 Equipment  
CASY Cell Counter System (Model DT, Schaerfe Systems, Reutlingen, Germany) 
Cell culture incubator, Cytoperm2 (Heraeus, Germany) 
Developing machine, X Omat 2000 (Kodak, USA) 
Electrophoresis chambers (Bio-rad, USA) 
Fluorescence microscope, Leica DMR (Leica Microsystems, Bensheim, Germany) 
Freezer -20 oC (Bosch, Germany) 
Freezer -40 oC (Kryotec, Germany) 
Freezer -80 oC (Heraeus, Germany) 
Fridge +4 oC (Bosch, Germany) 
Mini spin centrifuge (Eppendorf, Germany) 
Multifuge centrifuge, 3 s-R (Heraeus, Germany) 
Light microscope, Leica DMIL (Leica Microsystems, Bensheim, Germany) 
PCR thermocycler (MJ Research, USA) 
Pipetboy (Eppendorf, Germany) 
Pipetmans (Gilson, France) 
Power PAC 300 (Bio-Rad, USA) 
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Mini trans-blot chamber (Bio-Rad, USA) 
Vortex machine (Eppendorf, Germany) 
Film cassette (Sigma-Aldrich, Germany) 
Filter tips (Greiner Bio-One, Germany) 
Filter units 0.22 m syringe-driven (Millipore, USA) 
Gel blotting paper (Bioscience, Germany) 
Pipette tips (Sarstedt, Germany) 
Falcon tubes 15 and 50 ml (Greiner Bio-One, Germany) 
Tissue culture chamber slides (BD Falcon, USA) 
Tissue culture T75 flask (Greiner Bio-One, Germany) 
Tissue culture plates: 6 and 48 well (Greiner Bio-One, Germany) 
 
2.3 Methods 
2.3.1 Patient Population 
Human lung tissue was obtained from twelve IPAH subjects (meanSD age 3210 yrs, 
seven females, five males) who carried no BMPR2 mutations and no current treatment 
was effective, and nine control subjects (meanSD age 3814 yrs, five females, for 
males), which were rejected for transplantation, due to recipient incompatibility, with 
no systemic disorders or use of any medication. All control and IPAH derived tissue 
samples used in this study, were provided from the University of Vienna, as part of a 
collaboration with Dr Walter Klepetko (Department of Cardiothoracic Surgery, 
University of Vienna). Concerning the recipient incompatibility, there are several 
reasons this can occur. For example, there can be size incompatibility of the available 
lung to be transplanted, with the recipient. In addition, injured lungs or lungs derived 
from polytraumatised patients can rarely be used for transplantation. Therefore the 
lungs, which are not suitable for transplantation, are available for research purposes. 
The diagnosis of IPAH was made in accordance with the American Thoracic Society-
European Respiratory Society congress criteria and the Ethics Committee of the 
University of Giessen School of Medicine approved the study protocol. Informed 
consent was obtained from each subject for the study protocol. 
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2.3.2 RNA isolation and Polymerase Chain Reaction  
RNA from human lung homogenates was extracted using the Roth kit and from 
PASMC using the Qiagen Mini kit according to manufacturer's instructions. The RNA 
concentration was quantified using spectrophotometric analysis and reverse transcribed 
to cDNA using the Promega ImPro II reverse transcriptase, which uses RNA as 
template to generate cDNA. To perform the RT reaction, the RNA (100 – 500 ng/ml) 
was mixed with 1l of random hexamers in PCR tubes, heated at 70 oC for 10 min and 
then the reaction mix was added. 
Components Volume Final concentration 
5x RT buffer 
10 mM dNTP mix 
RNAsin inhibitor 
Reverse transcriptase 
(1 U/l) 
Rnase free water 
5 l 
0.5 l 
0.5 l 
0.5 l 
 
8.5 l 
1x 
0.2 mM 
0.5 U 
0.5 U 
 
 
   
The reverse transcription was performed as follows: 25 oC for 5 min, 42 oC for 1 h. 
The cDNA was further used for polymerase chain reaction (PCR) or stored at -20 oC. 
The PCR analysis is a method that allows the exponential amplification of specific 
DNA segments. The PCR is an enzymatic reaction, catalysed by a DNA polymerase. 
Polymerase chain reaction can be divided to three steps: denaturation (generation of 
single stranded DNA), annealing (primers bind to target sequence) and extension 
(amplification of DNA segment). Semi-quantitative PCR analysis was performed for 
human pai-1 gene (primer sequences for pai-1 (i) are found in table 1).  
 
Components Volume Final concentration 
5x RT buffer (MgCl2 free) 
10 mM dNTP mix 
25 mM MgCl2 
10 M forward primer 
10 M reverse primer 
DNA 
Taq polymerase  
(5 U/l) 
10 l 
1 l 
2 l 
1 l 
1 l 
1 l 
0.25 l  
1x 
0.2 mM 
1 mM 
0.2 mM 
0.2 mM 
 
1.25 U 
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The PCR band intensities were normalised to the loading control heat shock protein 70 
(hsc70). The densitometric analysis was performed with a GS-800TM Calibrated 
Densitometer using the Quantity One software (Bio-Rad Laboratories, Munich, 
Germany). Real-time PCR analysis was performed using the Sequence Detection 
System 7500 (Applied Biosystems, Wellesley, MA) for human pai-1, has1-3, hyal1-4, 
cd44 and rhamm, where human hypoxanthine phosphoribosyltransferase (hprt)-1, and 
hydroxymethylbilane synthase (hmbs), equally expressed genes without pseudogenes, 
were used as an internal control (Morty, Nejman et al. 2007). All the reagents were 
combined as indicated below and the final volume was adusted to 25l with 
autoclaved, distilled water. 
Components Volume Final concentration 
qPCR Supermix 
50 mM MgCl2 
10 M forward primer 
10 M reverse primer 
DNA 
13 l 
1 l 
0.5 l 
0.5 l 
1 l 
1x 
2 mM 
0.2 mM 
0.2 mM 
For each amplification, a threshold cycle (Ct) was recorded in the exponential phase of 
the amplification. The quantification of the relative gene expression levels was 
achieved using standard curves for both the target and internal control genes. The 
relative mRNA expression of a gene is expressed in Ct values (Ct = CtReference – 
Cttarget). Relative changes compared to controls are expressed as Ct values (Ct = 
Cttreated - Ctuntreated). The amplification of the specific PCR product was confirmed by 
melting curve analysis and gel electrohoresis. The primer sets work under identical 
real-time PCR cycling conditions to obtain simultaneous amplification.  
2.3.3 Protein Isolation and Western Blotting 
Protein extracts (100 g) from human lung tissues (donor=5, IPAH=5) and human 
primary PASMC were subjected to SDS-PAGE and western blotting with the 
following antibodies: anti-PAI-1 (Santa Cruz, 1:200 dilution), anti-GAPDH (Santa 
Cruz, 1:10000 dilution), anti-phosphorylated Smad2 (Cell Signaling, 1:1000 dilution), 
anti-Smad2 (cell signalling, 1:1000 dilution) and anti--actin (cell signalling, 1:1000 
dilution). The protein concentration was estimated with a Bio-Rad DC Protein Assay 
following manufacturer’s instructions (Bio-Rad, Hercules, USA). Briefly, human lung 
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tissue samples were homogenised in liquid nitrogen and suspended in lysis buffer  
(50 mM HEPES, pH 7.0, 250 mM NaCl, 5 mM EDTA, 1 mM DTT and 0.1 % triton-x 
100). One hundred g of protein were resuspended in Laemmli sample buffer (10 % 
(w/v) SDS, 10 mM -mercaptoethanol, 20 % (v/v) glycerol, 200 mM Tris-HCl, pH 6.8, 
and 0.05 % (w/v) bromophenol blue), resolved on a 10 % SDS-PAGE gel for 1.5 h at 
100 V, and blotted on a nitrocellulose membrane in a tank blotting system containing 
transfer buffer (24 mM Tris base, 193 mM glycine and 10 % (v/v) methanol) for 1 h at 
100 V at room temperature. Next, the membrane was blocked in blocking solution 
(5 % milk powder (w/v), 1x TBS, 0.01 % tween-20 (v/v)) for 1 h at room temperature. 
The membrane was incubated with the primary antibody overnight at 4 oC. Next, the 
membrane was washed with 1x TBST for 3 x 15 min and then a HRP-conjugated 
secondary antibody was applied in blocking solution for 1 h at room temperature. 
Washing with 1x TBST for 3 x 15 min followed and finally the membrane was 
incubated with the ECL-detection reagent to detect the primary antibody. The 
membrane would be stripped from the antibodies using a stripping buffer (0.1 M 
glycine, pH 2.9), in order other antibodies to be applied.      
2.3.4 Immunofluorescence 
The PASMC (104) were plated on an 8-well chamber slide, fixed with cold methanol at 
–20 C for 5 min and further stained for SMA (Sigma, 1:400 dilution), transgelin 
(SM22) (R&D, 1:1000 dilution) and Platelet Endothelial Cell Adhesion Molecule 
(PECAM)-1 (Dianova, 1:500 dilution). Furthermore, cells were stimulated with TGF-
1 (2 ng/ml) for 24 h and stained for PAI-1, (Santa Cruz, 1:250 dilution). Briefly, after 
fixation, and washing with 1x PBS, blocking solution (5% (v/v) FCS in 1x PBS) was 
added for 1 h at room temperature. Next, the primary antibody, diluted in 2.5 % (v/v) 
FCS, was added for overnight incubation. After washing with 1x PBS, the FITC-
labelled secondary antibody was added for 1 h at room temperature. The cells were 
washed with 1x PBS, covered with mounting mediun, containing DAPI nuclei 
visualisation. The slides where then analysed by fluorescent microscopy.  
2.3.5 Cytokine stimulation 
PASMC were cultured in the presence or absence of recombinant PAI-1 (rPAI-1) 
(R&D Systems, 200 ng/ml), TGF-1 (R	D Systems, 2 ng/ml) and Platelet Derived 
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Growth Factor (PDGF-BB, R&D Systems, 10 ng/ml)  
 Table 1: Primer sequences. The gene primers used for PCR analysis. for: forward, re: reverse 
Gene  sequences (5´  3´)  length 
has1 
for gcgatactgggtagccttca  20bp 
rev ggttgtaccaggcctcaaga  20bp 
has2 
for acagacaggctgaggacgac  20bp 
rev ctgtgattccaaggaggag  20bp 
has3 
for gtcatgtacacggccttcaa  20bp 
rev cctacttggggatcctcctc  20bp 
hyal1 
for gtgctgccctatgtccagat  20bp 
rev attttcccagctcacccaga  20bp 
hyal2 
for tctaccattggcgagagtg  19bp 
rev gcagccgtgtcaggtaat  19bp 
hyal3 
for gatctgggaggttcctgtcc  20bp 
rev agagctggagaggctcaggt  20bp 
hyal4 
for tgaggatctccaccatgaca  20bp 
rev ggcagcactttctcctatgg  20bp 
pai-1 (i) 
for atgcagatgtctccagccctc  21bp 
rev gatgaaggcgtctttccccag  21bp 
pai-1 (ii) 
for gagaaacccagcagcagatt  20bp 
rev tggtgctgatctcatccttg  20bp 
hsc70 
for tgtgtctgcttggtaggaatggtggta  27bp 
rev ttacccgtccccgatttgaagaac  24bp 
fibronectin 
for ccgaccagaagtttgggttct  22bp 
rev caatgcggtacatgacccct  20bp 
vitronectin 
for aacactttgccatgatgcag  20bp 
rev gctaatgaactggggctgtc  20bp 
collagen I 
for aatggtgctcctggtattgc  20bp 
rev ggaaacctctctcgcctctt  20bp 
hprt1 
for aaggaccccacgaagtgttg  20bp 
rev gctttgtattttgcttttcca  21bp 
cd44 
for cccagatggagaaagctctg  20bp 
rev gttgtttgctgcacagatgg  20bp 
rhamm 
for gttgtgcaccatctccaggt  20bp 
rev agctgaagcaggcaaggtag  20bp 
hmbs 
for gcacccacacacagcctac  19bp 
rev gtacccacgcgaatcactct  20bp 
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2.3.6 Immunohistochemistry  
Human paraffin-embedded lung sections (3 m) were stained with an SMA antibody 
(1:600, Sigma-Aldrich, Germany), a PAI-1 antibody (1:45, American Diagnostica), a 
HAS1 (1:100, Santa Cruz, CA, USA) and a HYAL1 antibody (1:100, Novus 
Biologicals, CO, USA) using the Histostain Plus Kit (Zymed, San Fransisco, USA), 
which is based on the great affinity of avidin for streptavidin. For removing the 
endogenous peroxidase activity, human lung sections were incubated in 1% (v/v) H2O2. 
Furthermore, after blocking, the sections were incubated overnight with primary 
antibody further washed and incubated with a biotinylated secondary antibody. Slides 
were developed for 5 min with diaminobenzidine (DAB) and counterstained with 
Mayer’s haematoxylin.  
For HA staining, specific biotinylated Hyaluronan Binding Protein (HABP) 
(Seigakaku Corporations, Japan) was used. In brief, formalin-fixed paraffin-embedded 
tissue sections were incubated at 48 C overnight. Then the sections were washed in 
fresh xylene, rehydrated in ethanol (100%-75%) and washed in 1x PBS twice. After 
cooking in citrate buffer for 20 min the sections were incubated in H2O2 to reduce the 
peroxidase activity. The slides were next washed with 1x PBS and the tissue blocked 
with 1% BSA in PBS for 30 min. Biotinylated HABP (1:25 dilution) was added next 
for overnight incubation at 4 C. The next day the sections were washed with 1x PBS 
and incubated with streptavidin conjugated to peroxidase enzyme for 1 hr. The 
peroxidase enzyme was localized using the Substrate chromogen mixture. The sections 
were finally counter stained with haematoxylin and images were captured. As controls, 
sections were incubated prior to stainig with 50U/ml of Streptomyces hyaluronidase 
for 3 h at 37 C, or without the biotinylated HABP.  
2.3.7 Isolation and Culture of human primary PASMC  
Human primary PASMC were explanted from arteries of donor and IPAH patient 
lungs as previously described (Rose, Grimminger et al. 2002). Briefly, pieces of a  
pulmonary artery were placed on a 3 mm plate and after removal of the intimal and 
adventitial layers (endothelial cells and fibroblasts), the medial layer containing only 
PASMC was cut to small pieces, plated on a 3 mm plate and cultured in culture 
medium containing 20% FCS and 1% antibiotics (penicillin, streptomycin). The 
PASMC were grown, and further cultured. Identification of PASMC was based on the 
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presence of SMA and SM22 and absence of PECAM-1. PASMC were cultured in 
smooth muscle cell growth medium enriched with complement mix at 37 °C in a 5% 
CO2, 95 % O2 atmosphere. Passages three to seven were used for experiments.  
2.3.8 Small interference RNA (siRNA) 
Small interference RNA technology (Alnylam Europe AG) was used to knock down 
PAI-1. Different siRNA duplexes were tested, and the sequence leading to more 
efficient knock down (5’-aaacaagucacccuacacuctst-3’) was used to transiently transfect 
PASMC. Cells of approximately 50-60% confluency were transfected with the PAI-1 
siRNA (200 nM) using LipofectamineTM  2000 Reagent (Invitrogen) at a ratio of 1 g 
siRNA to 2 l Lipofectamine following manufacturer’s instructions. The non-specific 
control siRNA was purchased from Ambion. 
2.3.9 Proliferation assay  
Freshly isolated human primary PASMC were plated onto a 48 well plate. After 24 h 
starvation in smooth muscle cell medium containing 0.5% supplement, cells were 
subjected to different conditions. After 24 h, [3H]-Thymidine was added to each well 
for 6 h. After washing for three times with 1x PBS, cells were lysed with 0.5 M NaOH. 
The incorporated [3H]-Thymidine content was determined by scintillation counting. 
Furthermore, PASMC were plated onto 6-well plates and after 24 h of starvation, 
transfected with scrambled or PAI-1 specific siRNA and then subjected to different 
conditions. The effects on cell growth were measured by cell counting using the CASY 
Cell Counter System. 
2.3.10 Migration/chemotaxis assay  
The ability of human primary PASMC to migrate to the chemotactic stimulus of 
PBGD-BB and rPAI-1 or after PAI-1 knock down with PAI-1 specific siRNA was 
assessed using a Boyden chamber (Neuro Probe, Gaithersburg, MD) as has been 
previously described (Chavakis, Cines et al. 2004). Briefly, 1 x 104 PASMC were 
placed on the upper compartment of the Boyden chamber, in serum free medium, and 
allowed to migrate to the undersurface of the membrane, which is coated with 
fibronectin (2 g/ml), and where the chemotactic factors are found. The extent of 
migration was assessed by the Quantity One software (Bio-Rad Laboratories) and 
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relative migration was expressed as optical density/mm2.  
2.3.11 Adhesion assay 
The adhesion of PASMC to collagen (2 g/ml), fibronectin (2 g/ml) and vitronectin 
(2 g/ml) in the presence or absence of rPAI-1 was assessed as it has already been 
described (Chavakis, Kanse et al. 2000). Briefly, 96-well plates were coated with 
collagen, fibronectin, vitronectin or BSA dissolved in bicarbonate buffer (pH 9.6) and 
blocked with 3% (w/v) BSA. PASMC were plated on the precoated wells in the 
presence or absence of rPAI-1 for 24 h.  After 30 min of incubation in serum-free 
medium, the cells were washed with 1x PBS and the adherent cells were fixed with 
methanol/acetone (1:1) and stained with crystal violet blue and the relative adhesion 
was quantified by measuring the absorbance at 590nm.  
2.3.12 GAG isolation and purification  
Lung tissue was homogenised by a Polytron homogenizer (5 x 10 s bursts with 1 min 
intervals in ice) in 10 ml of 25 mM Tris–HCl, pH 7.6, per g of tissue. Homogenised 
tissues were delipidated with chloroform/methanol (1:2 v/v). Organic solvents were 
removed by centrifugation (3,200 x g, 20 min, 4 C) and the pellet was washed with 10 
ml of ethanol, centrifuged and dried at 40 C for 4 h. The pellet was resuspended in 1 
ml of 0.1 M Tris-HCl buffer, pH 8.0, containing 1 mM CaCl2 and subjected to protein 
digestion with 0.1 KU of pronase (Streptomyces griseus). The pronase solution was 
preincubated for 30 min, at 60 C, in order to eliminate any glycosidase activity. 
Digestion was carried out for 72 h, at 60 C, by adding equal amounts of pronase at 24 
h intervals. The sample concentration was then adjusted to 150 mM NaCl and 10 mM 
MgCl2 and DNA digestion was accomplished by adding 400 KU DNase I and 
incubating for 16 h, at 37 C. At the end of the incubation period, the CaCl2 
concentration of the solution was adjusted to 1 mM and the reaction was stopped by 
adding 0.1 KU of pronase and incubating the mixture at 60 C, for 24 h. The pH was 
adjusted to 10-11 by addition of 10 mM NaOH and samples were subjected to -
elimination in the presence of 1 M NaBH4 for 16 h, at 45 C. Samples were then 
neutralized with 50% (v/v) acetic acid. Total GAGs were precipitated with the addition 
of four volumes of ethanol in the presence of 0.1 volume of 3 M CH3COONa and 
overnight maintenance at -4 °C, recovered with centrifugation (20 min, 2,000 x g), 
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redissolved in double distilled H2O and stored at 4 °C. Colorimetric determination of 
uronic acids was performed according to Bitter and Muir (Bitter and Muir 1962).  
2.3.13 Cellulose acetate electrophoresis 
Two l of the GAG solution, containing about 4 g of uronic acids, were placed at the 
origin (10 mm from the cathode side) of a cellulose acetate strip. Electrophoresis was 
carried out in 100 mM pyridine / 470 mM formic acid, pH 3.0, using 7 mA constant 
current, at room temperature, for 70 min. After electrophoresis, the cellulose acetate 
strip was stained with 0.2% Alcian blue (w/v), in 0.1% acetic acid (v/v), for 10 min 
and washed with 0.1% acetic acid (v/v) for 20 min (Papakonstantinou, Roth et al. 
1998). The intensity of the staining was quantified by the computer-assisted image 
analysis programme of Kodak. 
2.3.14 GAG characterisation 
Speed-dried GAGs (5 g of uronic acids) were incubated in a final volume of 15 l as 
follows: (a) Heparinase: samples dissolved in 100 mM Tris-HCl buffer, pH 7.0, 
containing 3 mM CaCl2 and incubated with 4 x 10-4 U of heparin lyase I (EC 4.2.2.7, 
Flavobacterium heparinum, Seikagaku, Tokyo), for 15 h, at 30 C. (b) Heparitinase: 
samples dissolved as above were incubated with 4 x 10-4 U of heparan sulphate lyase 
(Flavobacterium heparinum), for 16 h, at 43 C. (c) Chondroitinase ABC: samples 
dissolved in 100 mM Tris-HCl buffer, pH 8.0, containing 50 mM sodium acetate were 
incubated with 2 x 10-4 U of chondroitin ABC lyase (Proteus vulgaris) for 16 h, at 37 
C. (d) Chondroitinase B: samples dissolved in 100 mM Tris-HCl buffer, pH 7.4, were 
incubated with 0.1 U of chondroitin B lyase (Flavobacterium heparinum), for 16 h, at 
37 C. (e) Keratanase: samples dissolved in 50 mM Tris-HCl buffer, pH 7.4, were 
incubated with 0.05 U of keratan sulphate endo--D-galactosidase (Pseudomonas 
species) for 16 h, at 37 C. (f) Hyaluronidase: samples dissolved in 20 mM sodium 
acetate, buffered with acetic acid to pH 5.0, were incubated with 4 U of hyaluronate 
lyase (Streptomyces hyalurolyticus), for 14 h, at 60 C. 
Incubation times and enzyme concentrations used were those required for the complete 
degradation of their respective standard substrates, as estimated by a preliminary 
investigation. In this preliminary study, the standard GAGs (10 g) chondroitin 
sulphate A (bovine trachea), chondroitin sulphate B (porcine skin), chondroitin 
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sulphate C (shark cartilage), hyaluronic acid (bovine trachea), keratan sulphate (bovine 
cornea), heparan sulphate (bovine intestinal mucosa) and heparin, were treated 
individually with each of the above mentioned GAG-degrading enzymes following 
appropriate incubation procedures. Substrates incubated separately with their 
respective buffers served as controls. Digestion was evaluated by electrophoresis on 
cellulose acetate membranes and quantified by the computer-assisted image analysis 
programme of Kodak (Papakonstantinou, Karakiulakis et al. 1995).  
2.3.15 HA measurements  
Secretion of HA by primary PASMC: Cells were grown to high density in 24-well 
plates. Before the experiments, cells were washed two times with culture medium to 
completely remove HA that accumulated during cell growth. Subsequently, cells were 
cultured with or without TGF-1 (0.2, 2, 10 ng/ml) for 6, 12 and 24 h. At the end of 
incubation time, aliquots of medium were removed and tested for the presence of HA. 
Briefly, ELISA plates coated with HABP were incubated with supernatants and 
standards, respectively, for 1 h at room temperature in duplicates, washed five times 
with washing buffer, incubated with a solution containing horseradish peroxidase-
conjugated HA-binding protein for 1 h at room temperature, washed again five times, 
and incubated with 100 l of the provided substrate solution. After 20 min, the reaction 
was stopped by adding an equal amount of sulfuric acid (0.36 N), and after that the OD 
was measured at 450 nm (630-nm reference). 
Amount of HA in total GAGs: Total GAGs were isolated and purified from lung 
tissue specimens, as described above. The relative amount of HA was measured in 
aliquots of total GAGs containing 0.15 g of uronic acids by ELISA, following the 
same procedure, as described above. 
2.3.16 Measurement of total GAG synthesis 
Subconfluent primary PASMC were incubated for 24 h, in the presence or in the 
absence of TGF-1 (0.2 to 2 ng/ml), BMP2 (10 to 20 ng/ml), SB431542 (10 M), 
SB203580 (10 M) and PDGF-BB (10 ng/ml). In all cases, 3H-glucosamine (0.5 
Ci/ml) was added in the culture media. Culture medium and the cell layer (cells 
together with the ECM) were collected separately and digested with 0.1 KU of Pronase 
(Streptomyces griseus). Total GAGs were precipitated by adding a mixture of ethanol 
Materials and Methods 
31 
(80% final concentration) containing 1.3% (w/v) sodium acetate. The samples were 
stored at –20 C overnight and then centrifuged at 10,000 x g. The pellets were 
dissolved in 0.5 M NaOH and total GAG synthesis was assessed by measuring the 
amount of 3H-glucosamine incorporated into GAGs (Papakonstantinou, Karakiulakis 
et al. 2000).  
2.3.17 Statistical Analysis 
All data are expressed as mean  SEM (n 
 3). The different experimental conditions 
were compared using the student’s t-test for single measurements. The differences 
were regarded as significant when p< 0.05. All experiments were performed for at 
least three times.  
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3. Results 
3.1 PAI-1 expression in IPAH and donor lungs 
The PAI-1 expression levels both at the mRNA and protein level were investigated in 
human lung homogenates from donor and IPAH subjects. It was found that PAI-1 
expression was significantly downregulated in the IPAH patient samples at both the 
mRNA and protein level, as demonstrated by semi- and quantitative PCR, compared to 
donor samples (Fig. 7A-C). Since the levels of PAI-1 were measured in human 
samples, there is an expected variability among the different donor and IPAH patient 
lung samples.  
 
Figure 7: The mRNA and protein expression of PAI-1 in lung homogenates of 
IPAH patient and donors. (A) The pai-1 mRNA levels were investigated in donor (n = 7) and 
IPAH patient (n = 7) lung homogenates by semi-quantitative RT-PCR. The hsc70 gene served as a 
loading control. (B) The graphical representation of densitometric analysis of the results from three 
independent semi-quantitative RT-PCR experiments. * indicates p < 0.01. (C) PAI-1 protein levels were 
investigated in donor (n = 5) and IPAH patient (n = 5) lung homogenates by western blotting. GAPDH 
served as a loading control. Data are representative for at least three independent experiments. 
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3.2 PAI-1 localisation in the human lung 
The next step was to localise PAI-1 in the human lung. Human donor and IPAH 
patient lung sections were stained for PAI-1 and SMA, a marker of smooth muscle 
cells. Plasminogen activator inhibitor-1 was abundantly present and well distributed in 
the human lung. The PAI-1 localised to the bronchial and alveolar epithelial cells as 
well as to the PASMC and endothelial cells (Fig. 8).  
 
Figure 8: Localisation of PAI-1 in IPAH patient and donor lung tissue. (A) Adjacent 
donor and IPAH human lung sections were stained for SMA or PAI-1, as indicated. Magnification ×10 
      
Since PAI-1 is well distributed in the lung, it would be of major importance to show 
that PAI-1 levels are reduced in the arterial vessel wall and specifically in PASMC that 
play major role in IPAH development.  
 
Figure 9: Reduced levels of PAI-1 in IPAH-derived PASMC. PAI-1 mRNA levels were 
further assessed in primary PASMC isolated from donors (n = 3) and IPAH (n = 5) patient lungs by 
quantitative real-time PCR (qRT-PCR). Results are presented as mean±S.E.M.* indicates p < 0.05. 
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Therefore, to support the original observation that PAI-1 expression levels are 
decreased in patients with IPAH, and to demonstrate that this was due to lower 
expression in the vessel wall, PASMC from patients with IPAH were isolated, and the 
pai-1 levels were measured. Quantitative PCR analysis revealed that pai-1 is indeed 
downregulated in PASMC from IPAH patients (Fig. 9), suggesting that the reduced 
PAI-1 expression could influence the function of PASMC in the pulmonary vessel 
wall.  
3.3 TGF-1-dependent PAI-1 upregulation in PASMC 
It is known that PAI-1 levels is regulated by several cytokines, including TGF-1. It 
was interesting to elucidate whether TGF-1 regulates PAI-1 expression in PASMC as 
well. Therefore, PASMC derived from the pulmonary arteries of healthy controls were 
stimulated at different time-points with TGF-1, and the PAI-1 levels were measured 
at the mRNA and protein level by quantitative PCR and western blotting, respectively 
(Fig. 10 A, B).  
 
 
Figure 10: TGF-1-dependent PAI-1 regulation in PASMC. Human primary PASMC 
were stimulated for up to 48 h with TGF-1 (2 ng/ml), as indicated. The cells were harvested for RNA 
(A) and protein (B) extraction. The pai-1 mRNA levels were assessed by quantitative PCR (A), while 
PAI-1 protein levels were assessed by western blotting (B). Phospho-Smad2 was used as a positive 
control for TGF-1 stimulation, while -actin and total Smad2 served as loading controls. Results are 
presented as mean±S.E.M., * indicates p < 0.05 compared with unstimulated cells. Data are 
representative for at least three independent experiments. 
 
Indeed, TGF-1 elevated PAI-1 mRNA and protein levels in PASMC. Smad2 
phosphorylation is used as a positive control for the TGF-1 stimulation, since active 
TGF- signalling is indicated by Smad phoshorylation.  
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3.4 PAI-1 localisation in PASMC 
Next, PAI-1 was localised in PASMC before and after TGF-1 stimulation. As 
visualised by immunofluoresence staining, PAI-1 localised mainly in the perinuclear 
(since it is a secreted factor) as well as cytoplasmatic (suggesting an intracellular 
function too) areas of PASMC (Fig. 11B). The purity of the isolated PASMC culture 
was tested with staining for SMA, SM22 (both are smooth muscle markers) and 
PECAM (an endothelial marker) (Fig. 11A). 
 
Figure 11: Localisation of PAI-1 in cultured PASMC. Human primary PASMCwere 
isolated from donor pulmonary arteries for in vitro experiments. (A) The purity of primary PASMC was 
assessed by positive staining for SMA and SM22 (transgelin), which are specific smooth muscle cell 
markers. In contrast, staining for the endothelial cell marker PECAM-1 was routinely negative. (B) 
Human primary PASMC were stimulated with TGF-1 (2 ng/ml) for 24 h, fixed in ice-cold methanol 
and stained for PAI-1. Magnification ×63 and 40× in (A) and (B), respectively. 
3.5 PAI-1 regulates PASMC proliferation 
In order to investigate further how the downregulation of PAI-1, observed in IPAH 
lung homogenates as well as in IPAH patient lung-derived PASMC, affects cellular 
processes, in vitro experiments were performed in primary human PASMC. The 
PASMC were stimulated with active recombinant PAI-1 (rPAI-1) (200 ng/ml) for 24 h 
and their proliferation was measured by [3H]-Thymidine incorporation (Fig. 12A). 
Addition of exogenous rPAI-1 induced a significant decrease in cell proliferation 
compared to control serum and PDGF-BB stimulation, a known PASMC proliferation 
inducer. However, PAI-1 could not reverse the proliferative effect of PDGF-BB on 
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PASMC. The opposite experiment was performed as well, to further confirm the above  
described results. 
 
Figure 12: PAI-1 inhibits PASMC proliferation. (A) Human primary PASMC were 
cultured in serum-free medium for 24 h and then stimulated with recombinant (r)PAI-1 (200 ng/ml), 
PDGF-BB (10 ng/ml), or both for another 24 h. [3H]-thymidine incorporation was determined 24 h after 
stimulation. Primary human PASMC were transfected with PAI-1-specific or scrambled siRNA in 
serum-free medium for 4 h, supplemented with normal, serum-containing medium for another 24 h, and 
the knock-down efficiency was evaluated by quantitative PCR (B) and western blotting (C). After a 
further 24 h, the cells were further stimulated with rPAI-1 (200 ng/ml), and cell number was measured 
by cell counting using the CASY Cell Counter System (D). Data are representative of at least three 
independent experiments. * indicates p < 0.05 compared with unstimulated (control) cells.  
 
In more detail, PASMC were transfected with a specific PAI-1 small interfering RNA 
(siRNA), which caused significant PAI-1 knock down at both the mRNA and protein 
level (Fig. 12B, C). PASMC proliferation was assessed by cell counting after siRNA 
transfection. PAI-1 knock down increased PASMC proliferation (Fig. 12D) compared 
to PASMC transfected with scrambled siRNA. Furthermore, treatment of the 
transfected PASMC with PAI-1 siRNA with rPAI-1 reversed the effect of PAI-1 knock 
down (Fig. 12D). 
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3.6 PAI-1 Regulates PASMC Migration and Adhesion  
Next, the effects of PAI-1 on PASMC migration, a function which also contributes to a 
certain extent to vascular remodelling as well, was investigated. Plasminogen activator 
inhibitor 1 regulated the migration of PASMC on fibronectin-coated membranes (Fig. 
13A), as indicated by the Boyden chamber chemotactic assay. More specifically, 
incubation of PASMC with active rPAI-1 significantly increased PASMC migration 
compared to control medium and PDGF-BB stimulation, a known inducer of PASMC 
migration. Furthermore, transfection with PAI-1 siRNA decreased the migration levels 
of PASMC compared to scrambled siRNA- transfected cells (Fig. 13B).  
 
 
Figure 13: PAI-1 induces PASMC migration. Human primary PASMC were stimulated 
with rPAI-1 (200 ng/ml) or PDGF-BB (10 ng/ml) (A), or transfected with PAI-1-specific or scrambled 
siRNA (B), and cell migration was measured in a Boyden chamber migration assay. PDGF-BB was 
used as a positive control for PASMC migration. * indicates p < 0.05 compared with unstimulated 
(control) cells. Data are representative of at least three independent experiments. 
 
The final step was to assess PAI-1 influence on PASMC adhesion, on differently 
coated surfaces. The PASMC were cultured on fibronectin-, vitronectin-, and collagen 
type I-coated plates, in the presence or absence of active rPAI-1. Incubation of 
PASMC with rPAI-1 resulted in decreased cell adhesion to vitronectin, whereas no 
significant effects were observed on PASMC adhesion to fibronectin or collagen type I 
(Fig. 14A). The above results agree with already published data on PAI-1 being a co-
factor for vitronectin and thus compete with the cell’s integrins for binding to 
vitronectin. Thus the cell looses its ability to adhere to the surrounding matrix.  
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Figure 14: PAI-1 reduces PASMC adhesion on vitronectin. (A) The adhesion of human 
primary PASMC to fibronectin-, vitronectin-, and collagen I-coated plates was evaluated in the presence 
or absence of rPAI-1 (200 ng/ml). The rPAI-1 significantly decreased the adhesion of PASMC to 
vitronectin-coated plates. BSA was used as a control. * indicates p < 0.02 compared with unstimulated 
cells. (B) The expression levels of the three coating substrates used in the adhesion assay (fbronectin, 
vitronectin, or collagen I) was investigated in donor and IPAH samples (n = 7 each) using  quantitative 
PCR. Fibronectin and vitronectin were significantly upregulated in IPAH human lung homogenates. * 
indicates p < 0.05. 
 
To interpret the effects of PAI-1 on cell adhesion to vitronectin and to correlate these 
effects with disease, the mRNA levels of fibronectin, vitronectin and collagen I were 
investigated in donor and IPAH lung homogenates by quantitative PCR (Fig. 14B). 
Both fibronectin and vitronectin were upregulated in the IPAH samples, whereas 
collagen type I levels did not exhibit any differential expression between the two 
groups.      
3.7 Differential expression of GAGs in IPAH  
Total GAGs were isolated and purified from lung tissue samples obtained from IPAH 
patients and healthy donors. The fractionation of total GAGs (4 g of uronic acids) by 
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electrophoresis on cellulose acetate membranes revealed that both in the donor and 
IPAH lung homogenates, four distinct GAG populations, G1, G2, G3 and G4 (Fig. 
15A) were present. These GAGs migrated with the same mobility as hyaluronic acid 
(HA), heparan sulphate (HS), dermatan sulphate (DS) and chondroitin sulphate (CS), 
respectively. Enzymatic treatment with specific GAG-degrading enzymes (Table 2) 
confirmed that: G1 was HA, since it was completely degraded only by hyaluronidase; 
G2 was HS, as it was completely degraded only by heparitinase; G3 was DS, since it 
was completely susceptible only to chondroitinase ABC, and chondroitinase B; and G4 
was CS, as it was degraded only by chondroitinase.  
 
Table 2: GAG identification. Total glucosaminoglycans isolated and purified from human lung  
tissue samples were treated with GAG-degrading enzymes. 
 
 
Alcian blue staining of cellulose acetate membranes and quantitation of the intensity of 
the staining by a computer-assisted image analysis programme revealed quantitative 
differences in the relative amount of the above-described GAGs between IPAH patient 
and donor lungs (Fig. 15B). In particular, a significant increase (p<0.01) in the relative 
content of HA in parallel with a significant decrease in the relative content of HS 
(p<0.02), DS (p<0.01) and CS (p<0.01) was observed in IPAH tissue specimens, 
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compared to donors (Fig. 15B).  
 
 
Figure 15: GAG expression in IPAH. (A) Representative cellulose acetate membranes 
demonstrating the electrophoretic separation of total GAG in donor and IPAH lung specimens. G1–G4: 
four detectable GAG peaks in lung tissues. Commercially available GAG standards were as follows. 
HA: hyaluronic acid; HS: heparan sulphate; DS: dermatan sulphate; CS: chondroitin sulphate. (B) 
Densitometric quantitation of mean±SEM values of alcian blue staining of the electrophoretic separation 
of GAGs. (C) Measurement by ELISA of the relative content of HA in aliquots of total GAG containing 
0.15 mg of uronic acids. Data are presented as meanSEM. For all investigations, samples from four 
donor and five IPAH lung tissue specimens were used. * indicates p<0.01. 
 
To quantify this increase in the HA levels, the amount of HA in total GAGs (0.15 g 
of uronic acids) isolated from IPAH and donors was measured by ELISA. The relative 
amount of HA in IPAH lung homogenates is significantly higher (p<0.01) as compared 
to tissue samples from donors.  
3.8 Changes in exrpression of has1, cd44 and hyal1 in IPAH 
The next question to be addressed was whether the observed increase of HA in IPAH 
is a result of increased synthesis or decreased degradation of HA. For this reason, the 
expression of has and hyal isoforms in IPAH patient and donor lungs were 
investigated by quantitative PCR. has1 expression levels were significantly higher (Fig. 
16A) and hyal1 expression levels were significantly lower (Fig. 16A) (p<0.05) in 
IPAH patient lung tissues compared to tissue from donors as demonstrated by 
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quantitative PCR.  
 
 
 
Figure 16: Differential expression of has1, hyal1, cd44 in lungs of IPAH patients. 
(A) mRNA was extracted from lung specimens obtained from IPAH patients and donors and the relative 
expression levels of has1–3, hyal1–4, cd44 and rhamm were measured by quantitative PCR. Data are 
presented as meanSEM relative expression level, as change in threshold cycle (Ct) values. * indicates 
p<0.05. (B) HAS1 protein levels (66 kDa) were investigated in lung homogenate samples from donors 
or IPAH patients by western blotting. GAPDH (38 kDa) served as a loading control. Data are 
representative of at least three independent experiments. 
 
No significant differences were observed for has2, has3, hyal2, hyal3 or hyal4 
isoforms between IPAH and controls (Fig. 16A) on the mRNA level. 
Moreover, the expression of the HA receptors cd44 and rhamm was investigated. As 
depicted in Fig. 15A, IPAH is associated with significantly increased expression of 
cd44 levels compared to controls (p<0.05). There were no significant differences in the 
expression of rhamm between IPAH and donors (Fig. 16A). The increase in has1 
mRNA level was further confirmed on the protein level as well (Fig. 16B). 
3.9 IPAH is associated with increased distribution of HA in the lung 
In order to investigate whether the increased amounts of HA measured in lungs from 
IPAH was associated with differential distribution of HA, immunohistochemical 
analysis was performed in IPAH patient and donor lung sections, using HABP. A 
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considerably higher distribution of HA in IPAH lungs as compared to controls (Fig. 
17) was demonstrated. 
 
Figure 17: Localisation of HA in IPAH patient and donor lung tissue. The 
localisation of SMA, HABP, HAS1 and HYAL1 in pulmonary arteries of control donors and IPAH 
patients was investigated. HA was visualised by staining with HABP. Sections are representative for at 
least four different donors or IPAH patients. Scale bar 50 mm. 
3.10 TGF-1 Stimulates GAG Secretion and Deposition by PASMC  
Since TGF-1 is a key modulator of ECM components, the effect of TGF-1 on total 
GAG secretion and deposition in primary cultures of PASMC was investigated by 
measuring the incorporation of [3H]-glucosamine into GAGs. Transforming growth 
factor-1 significantly enhanced both the secretion (p<0.01) and deposition (p<0.05) 
of total GAGs by PASMC (Fig. 18A) at concentrations above 0.2 ng/ml. This effect 
was comparable with the effect of PDGF-BB (10 ng/ml), which has been previously 
shown to be a potent stimulator of GAG synthesis by vascular smooth muscle cells. 
Bone morphogenetic protein 2 (20 ng/ml) did not influence the secretion and 
deposition of total GAGs (Fig. 18A). In order to elucidate whether the TGF-1 
stimulatory effect on GAG synthesis by PASMC occurred in a TGF-RI-dependent 
manner, a specific inhibitor of TGF-RI, SB431542, was utilised and its effect on 
[3H]-glucosamine incorporation into GAGs was evaluated. SB431542 (10 M) 
significantly inhibited the basal secretion (p<0.01) and deposition (p<0.01) of total 
GAGs by PASMC (Fig. 18B). Furthermore, SB431542 inhibited the stimulatory effect 
of TGF-1 (2 ng/ml) on GAG secretion (p<0.01) and deposition (p<0.01) (Fig. 18B).  
Since TGF-1 can induce a Smad-independent signaling cascade, the effect of 
inhibiting the p38 MAPK pathway on TGF-1-induced GAG secretion and deposition 
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was investigated.  
 
Figure 18: Effect of TGF-1 on GAG secretion and deposition in PASMC. (A) 
Subconfluent PASMC were incubated with PDGF-BB, TGF-1 or BMP-2 for 24 h, in the presence of 
[3H]-glucosamine at 0.5 mCi/ml. Incorporation of [3H]-glucosamine was then assessed in supernatants 
(representing secreted GAG, shaded bars) and cell layers (representing deposited GAG, white bars). (B) 
Subconfluent PASMC were stimulated with TGF-1 in the presence or absence of the p38 MAPK 
inhibitor SB203580 or the type I TGF-1 receptor kinase inhibitor SB431542, and the incorporation of 
[3H]-glucosamine was assessed. Data are presented as meanSEM, n=4 for each treatment. #: p<0.005 
compared with control values; **: p<0.01 compared with TGF-1-stimulated values. 
 
Therefore, a specific p38 MAPK inhibitor, SB203580, was used and the effects on 
[3H]-glucosamine incorporation into GAGs by PASMC were measured. The 
SB203580 (10 M) significantly inhibited the basal secretion (p<0.02) of total GAGs 
by PASMC (Fig. 18B). However, SB203580 did not affect the basal [3H]-glucosamine 
incorporation into GAGs associated with the cell layer. However, SB203580 
significantly inhibited the stimulatory effect of TGF-1 (2 ng/ml) on GAG secretion 
(p<0.01) and deposition (p< 0.01), indicating that this effect is also mediated by the 
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p38 MAPK pathway.  
3.11 TGF-1 stimulates HA secretion by PASMC 
In order to investigate whether the TGF-1-induced [3H]-glucosamine incorporation is, 
in part, a result of increased HA secretion a time course (6-24 h) stimulation of 
PASMC with various concentrations of TGF-1 (0.2-10 ng/ml) was performed and 
then measured the secretion of HA in the supernatant by ELISA. Transforming growth 
factor-1 exhibited a time- and dose-dependant stimulatory effect on HA secretion by 
PASMC. The time-dependent effect of TGF-1 was significant after 12 h of incubation 
(p<0.02) at the higher dose of TGF-1 (10 ng/ml) and after 24 h at lower dose 
(p<0.01). Compared to the lower dose of TGF-1, the dose-dependent effect was 
significant at 10 ng/ml after 12 h of incubation, (p<0.05), and at 2 ng/ml after 24 h of 
incubation (p<0.05), reaching a plateau effect (Fig. 19). 
 
Figure 19: Effect of TGF-1 on HA secretion by PASMC. Subconfluent PASMC were 
incubated without TGF-1 or with 0.2 ng/ml, 2 ng/ml or 10 ng/ml for 6, 12 or 24 h. HA was measured 
in cell culture supernatants by ELISA. Data are presented as meanSEM of four independent 
experiments. * indicates p<0.05. 
3.12 TGF-1 Regulates has1 Expression in PASMC 
To elucidate whether the TGF-1-induced secretion of HA is a result of increased 
synthesis or decreased degradation of HA, the expression levels of has and hyal
isoforms were investigated by quantitative PCR. Interestingly, has1 expression was 
significantly upregulated by TGF-1 (2 ng/ml) (p<0.01). Transforming growth factor-
1 had no significant effect on the expression of has2, has3, hyal1, hyal2 and hyal3. 
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In addition, TGF-1 did not alter the expression of the receptors of HA, cd44 and 
rhamm (Fig. 20). 
 
Figure 20: Induction of has1 gene expression in TGF-1-stimulated PASMC. 
mRNA was extracted from primary human PASMC (n=3) without TGF-1 or from PASMC stimulated 
for 2 h or 6 h with 2 ng/ml of TGF-1. The relative expression levels of has1–3, hyal1–3, cd44 and 
rhamm were determined by quantitative PCR. Data are presented as meanSEM relative expression 
level, as change in threshold cycle (Ct) values. * indicates p<0.05. 
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4. Discussion 
This study focused on the role of the TGF- signalling pathway in the development of 
PAH. In particular, the canonical TGF- signalling cascade and its targets was 
screened in lung homogenates from IPAH patients and control groups, in order to 
identify differentially regulated genes that might regulate the function of PASMC, and 
thus, the process of pulmonary vascular remodelling. Particular interest was also paid 
to the role of TGF- on glucosaminoglycans and hyaluronic acid synthesis and 
deposition in the pulmonary arteries of IPAH patients. 
4.1 Differential expression of PAI-1 in IPAH 
The screening of the canonical TGF- signalling pathway revealed that PAI-1 was 
differentially expressed in lung homogenates from patients with IPAH in comparison 
to healthy donors. It was demonstrated that PAI-1 levels are significantly 
downregulated in IPAH human lung homogenates at both the mRNA and protein level 
as well as in IPAH derived PASMC. Immunohistochemical analysis of donor and 
IPAH lung sections revealed that PAI-1 was abundantly expressed in the lung, and in 
particular, found in the bronchial and alveolar epithelial cells as well as in PASMC, 
but clearly less expressed in IPAH lung sections.  
Furthermore, PAI-1, which was upregulated by TGF-1 in PASMC, controlled the 
proliferation, migration and adhesion of PASMC. Recombinant PAI-1 inhibited the 
proliferation of PASMC, as well as PASMC adhesion to vitronectin-coated plates, 
whereas PAI-1 induced migration of PASMC on fibronectin. These results were 
further confirmed by PAI-1 knock down with specific siRNA. Therefore, the current 
report indicates a possible relation between PAI-1 and the dysregulated PASMC 
behaviour observed in IPAH. 
4.2 Plasminogen activator inhibitor 1  
Plasminogen activator inhibitor 1 belongs to the serpin superfamily of protease 
inhbitors, it is secreted by a variety of different cells and is the main inhibitor of 
plasmin activation (Ryan and Higgins 1994). The PAI-1 is the physiological inhibitor 
of urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator 
(tPA). uPA and tPA activate plasminogen to give plasmin by preoteolytic cleavage 
(Fay, Garg et al. 2007). It is interesting that uPA, apart from its proteolytic effects, can 
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also initiate an intracellular signalling cascade, by binding to urokinase-type 
plasminogen activator receptor (uPAR) on the cell surface. Therefore, PAI-1 can 
regulate the uPA activity, by interacting directly with uPA and thus induce its 
internalization and lysosomal degradation, or by interacting with the uPA-uPAR, and 
inducing their internalization and degradation (Olson, Pollanen et al. 1992).  
Plasminogen activator inhibitor 1 is found in an inactive form, unless bound to the 
ECM protein vitronectin. To date, studies have demonstrated that PAI-1 is a 
multipotent factor, regulating different biological processes, apart from its well-
characterised role in the coagulation cascade.  
Plasminogen activator inhibitor 1 has been described to be a causative factor in fibrotic 
and cardiovascular diseases (Kohler and Grant 2000), (Sobel, Taatjes et al. 2003). 
Transgenic animals overexpressing PAI-1 develop vascular thrombosis (Eren, Painter 
et al. 2002) with increasing age. Furthermore, PAI-1 has also been involved in 
neointima formation. There is a significant decrease in vascular smooth muscle cell 
(VSMC) neontima formation in PAI-1 -/- mice, in response to oxidative stress-induced 
vascular injury (DeYoung, Tom et al. 2001). 
4.3 PAI-1 and the vessel wall 
The actual mechanisms how PAI-1 regulates the function of the cells in the vessel wall 
is rather complex and not fully elucidated yet.  It has been reported that PAI-1 can 
compete with cellular integrins for vitronectin binding (Stefansson and Lawrence 
1996; Stefansson, Lawrence et al. 1996), thus smooth muscle cells (SMC) are less 
adherent to the substrate (Kanse, Chavakis et al. 2004). These data are in agreement 
with the observations in the present study, where recombinant PAI-1 reduced the 
PASMC adherence only in the presence of vitronectin. The PAI-1 did not affect 
cellular adherence on fibronectin or collagen type I-coated surfaces. To correlate this 
PAI-1 effect on cell adhesion with the development and progression of IPAH, the 
mRNA levels of fibronectin, vitronectin, and collagen type I were investigated in 
donor and IPAH patient lung homogenates. It was observed that fibronectin and 
vitronectin levels were significantly upregulated in IPAH samples, whereas collagen 
levels remained unchanged. Although a recent study presented that vitronectin is 
downregulated in serum of IPAH patients (Yu et al., 2007), this finding, in 
combination with the decreased PAI-1 levels, suggest that in the final stages of IPAH, 
PASMC adhere more to the surrounding environment and thus proliferate more. 
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The effects of PAI-1 on vascular remodeling, in different cell types and experimental 
models, have not been clarified (Stefansson and Lawrence 2003; Stefansson, 
McMahon et al. 2003). High levels of PAI-1 have been reported in angiogenesis 
(Bajou, Maillard et al. 2004) and tumour formation, cancer metastasis (Bajou, Noel et 
al. 1998), radiation therapy (Milliat, Francois et al. 2006) and atherosclerosis 
(Schneider, Hayes et al. 2004). Several factors, such as NO (Baylis, Mitruka et al. 
1992), hypoxia, urotensin II, angiotensin II and TGF-1 that are implicated in the 
development of vascular diseases, regulate PAI-1 levels (Preissner, May et al. 1997; 
Shen 1998). 
The controversy surrounding the effects of PAI-1 continues at the cellular level, since 
it is not clear whether PAI-1 acts as an antiapoptotic or proapoptotic factor (Al-Fakhri, 
Chavakis et al. 2003; Chen, Budd et al. 2006) In addition, the effects of PAI-1 on 
smooth muscle cell migration remain to be defined, since under different conditions, 
PAI-1 can have a biphasic effect (Carmeliet, Moons et al. 1997; Samarakoon, Higgins 
et al. 2005). It is accepted, however, that PAI-1 is an important controller of vascular 
homeostasis.  
4.4 Plasminogen inhibitor type 1 in IPAH 
The role of PAI-1 in the pulmonary vascular remodelling and in the development of 
PAH has not been extensively investigated. IPAH is a rare and fatal disease, 
characterised by excessive pulmonary vascular remodelling, with fibrosis of the 
intimal layer, as well as hypertrophy and hyperplasia of the medial and adventitial 
layers, leading finally to occlusion of the vessels.  
It has been shown that high levels of PAI-1 are present in the blood of patients with 
PAH, leading to impaired fibrinolysis; however, PAI-1 levels are normal in 
bronchoalveolar lavage fluids of PAH patients (Christ, Graf et al. 2001). Furthermore, 
elevated levels of PAI-1 are responsible for the stabilisation of the thrombi observed in 
patients with chronic pulmonary thromboembolism (Lang, Marsh et al. 1994). It has 
been suggested, however, that such a fibrinolytic imbalance cannot be considered a 
generalised phenomenon in these patients (Lang, Marsh et al. 1994). 
According to the results obtained in the present study, PAI-1 levels were 
downregulated in lung homogenates from late phase IPAH patients as compared to 
healthy donors. Several reasons might explain this discrepancy. First, the increased 
levels of PAI-1 in the blood of patients with IPAH could have originated from the liver 
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or the adipose tissue, and thus may not accurately represent the actual levels in the 
pulmonary vasculature. Secondly, in the present study, the levels of PAI-1 were 
measured in tissues derived from explanted diseased lungs, thus the patient population 
was at the final stage of IPAH, whereas in the published literature, the disease stage of 
the patient population is unclear, thus it is difficult to compare the two studies.  
Taken together, the above results suggest that PAI-1 is a potent regulator of PASMC 
function and disturbance in the expression of PAI-1 could regulate the process of 
vascular remodelling during PAH development. In particular, at an early stage PAI-1 is 
upregulated, inducing PASMC migration, whereas at a later stage, decreased PAI-1 
levels allow the proliferation of PASMC, leading to the thickening of the medial layer 
of the pulmonary arteries.  
4.5 The role of HA in IPAH 
The second point of this study concentrated on the ECM, a critical factor for cellular 
viability and growth. It has already been shown that TGF-1 is not only important for 
regulating cellular processes such as cell proliferation, migration and adhesion, but 
also for ECM deposition (Roberts and Sporn 1989). Transforming growth factor-1 
regulates fibronectin and collagen, which are primary components of the ECM. In 
addition, glucosaminoglycans and hyaluronic acid, which are also components of the 
ECM, are important for lung homeostasis and proper cellular function. 
Glucosaminoglycans are known to play a significant role in inflammatory and 
noninflammatory lung diseases, inducing different effects on epithelial or 
mesenchymal cell types (Papakonstantinou, Roth et al. 2001; Jiang, Liang et al. 2005; 
Noble and Jiang 2006). Furthermore, GAGs regulate water homeostasis, cell and tissue 
hydration, structure and function, tumour progression, invasion and metastasis, as well 
as tissue repair and remodelling (Souza-Fernandes, Pelosi et al. 2006). This might 
suggest that differential secretion of GAGs by PASMC is associated with the vascular 
remodelling observed in IPAH. In the present study, expression of HA, the major GAG 
produced by PASMC, was significantly increased in IPAH lung tissues. Although the 
relative amount of HA was increased, the levels of the sulfated GAGs, such as 
heparan, dermatan and chondroitin sulfate were decreased, revealing an increased non-
sulfated-to-sulfated GAG ratio. The increased HA content of IPAH lung tissues was 
associated with increased and decreased gene expression of has1 and hyal1, 
respectively. Furthermore, PASMC derived from the lungs of IPAH patients 
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demonstrated a significant decrease in hyal1 mRNA levels compared with PASMC 
obtained from control donor lungs.  
Further in vitro experiments indicated that stimulation of PASMC with TGF-1 led to 
increased has1 gene expression as early as 2 h after stimulation. This indicated that 
TGF-1 can directly regulate the levels of HA in the pulmonary vessels. The increased 
HA staining observed in remodelled pulmonary arteries might indicate that HA 
secretion by PASMC can influence endothelial and smooth muscle cell proliferation 
and may regulate vasoreactive responses in IPAH. The latter idea is further supported 
by the observations that selective overexpression of has2 in smooth muscle cells in 
transgenic mice results in increased HA content in the tunica media, enhanced 
mechanical stiffness and strength and accelerated the development of atherosclerosis 
(Chai, Chai et al. 2005). It has been further reported that signalling through the HA 
receptor CD44 can regulate smooth muscle cell function and disease development. The 
expression of CD44 promoted susceptibility to atherosclerosis, macrophage 
recruitment and smooth muscle cell activation and proliferation (Cuff, Kothapalli et al. 
2001; Pure and Cuff 2001). It is interesting that no pulmonary vascular changes have 
been investigated thus far in these studies. It is highly likely that the observed changes 
in HA and CD44 levels in human pulmonary arteries, in the present study, can affect 
the pulmonary vascular stiffness and hence contribute to the increased resistance 
observed in IPAH.  
Further exloring the manner in which HA might regulate different cellular processes, it 
is known that HA binds 1000 times its own mass in water, and, therefore, contributes 
to tissue hydration. Also, it has been reported that increased HA synthesis and turnover 
occurs during both lung inflammation and mesenchymal cell activation. Hyaluronic 
acid regulates cellular processes, such as migration, differentiation and proliferation by 
interacting with cell-surface receptors, such as CD44 or RHAMM (Turley, Noble et al. 
2002), but also by interacting with the toll-like receptors 2 and 4 (TLR 2, 4) (Jiang, 
Liang et al. 2005). The HA-RHAMM interaction regulates focal adhesions as well as 
cytoskeletal changes required for cellular motility, which is also seen in cancer 
invasion and metastasis. The HA-CD44 interaction regulates processes, such as 
leukocyte migration and activation, and tumour invasion and metastasis. Furthermore, 
CD44-dependent clearance of HA fragments is crucial in resolving lung inflammation 
in the bleomycin model of lung injury, indicating an important role for CD44 in the 
resolution of inflammation.  
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4.6 Hyaluronic acid: Jekyll or Hyde 
A factor regulating HA effects is the average molecular mass (Turino and Cantor 
2003). Under physiological conditions, HA is a polymer of high molecular mass 
(1,000 kDa). The HA fragments of lower molecular mass accumulate after tissue 
injury, and are cleared by binding to CD44. In addition, low molecular mass HA (300–
500 kDa) has been reported to prolong the survival of eosinophils in vitro (Ohkawara, 
Tamura et al. 2000), and even lower molecular mass HA fragments (200 kDa), which 
induce the expression of chemokines or inducible nitric oxide synthase by 
macrophages, affect ECM turnover in murine alveolar macrophages (McKee, Penno et 
al. 1996). It has been demonstrated that HA can play diverse roles depending on 
molecular mass. Hyaluronic acid of a molecular mass of 250 kDa induces the 
expression of inflammatory genes, while HA of higher molecular mass exhibits the 
opposite effect, and suppresses chemokine expression (Joddar and Ramamurthi 2006). 
Therefore, it would be of great interest to elucidate in future studies whether HA 
expressed in the vascular system of control donor lung specimen is of different average 
molecular mass than in IPAH specimens. In this context, dysregulation of has/hyal 
expression and/or activity may lead to the generation of HA of different molecular 
masses, thereby exhibiting distinct biological effects, for example, facilitating PASMC 
migration and proliferation, which potentially contribute to the pathogenesis of IPAH. 
The changes in has/hyal expression, along with the change in HA synthesis and 
content in lungs of patients with IPAH, may also potentially result from the tissue 
hypoxia observed in the lungs of patients with IPAH. Notably, it has previously been 
reported that hypoxia potentiates GAG synthesis by primary lung fibroblasts induced 
by TGF-1 or PDGF-BB, suggesting that hypoxia is a synergistic regulator of the 
increased GAG deposition observed in IPAH (Papakonstantinou, Roth et al. 2002).  
4.7 Conclusion and future directions 
Taken together, the results of the present study demonstrate that TGF-1 can regulate 
PASMC processes, such as proliferation, migration and adhesion via PAI-1 and 
pulmonary vascular elasticity and resistance, by controlling the levels of HA in the 
lung and the enzyme that regulates HA synthesis.  
It has to be investigated more in depth the exact signalling mechanism of TGF--
induced PAI-1 levels in PASMC, which provide insight into other potentially 
interesting cascades involved in pulmonary vascular remodelling. A microarray 
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analysis in PASMC cells stimulated with TGF-1 would be worth doing, since it 
would reveal novel TGF-1 regulated genes that would be very useful for better 
understanding of vascular remodeling. 
In terms of the HA regulation, it seems that synergistic regulation of 
glycosaminoglycan-metabolising enzymes in favour of accumulation may, thus, 
regulate the pathological vascular remodelling observed in IPAH, by favouring an 
activated state of PASMC. It would be exciting to investigate the function of HA of 
different molecular mass to identify any differential effects on PASMC function. 
Furthermore, inhibition of the TFG- signalling cascade in animal models of PAH 
would be an efficient tool to investigate in depth and understand the exact mechanism  
and the regulation of pulmonary vascular remodelling.
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